Patent Application
20240132531
The present invention relates to novel compounds, the use of said compounds as medicament and for the manufacture of a medicament for the treatment of diseases or disorders such as but not limited to cancers; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; pathological angiogenesis; eye diseases; HIV-1 diseases; inflammation or transplant rejection in mammals. The invention also relates to pharmaceutical compositions comprising said novel compounds.
Galectins are proteins with a characteristic carbohydrate recognition domain (CRD). This is a tightly folded β-sandwich of about 130 amino acids (about 15 kDa) with the two defining features 1) a β-galactose binding site and 2) sufficient similarity in a sequence motif of about seven amino acids, most of which (about six residues) make up the β-galactose binding site. Galectins are synthesized as cytosolic proteins from where they can be targeted to the nucleus, specific cytososlic sites, or secreted to engage in mechanisms effecting physiological functions such as inflammation, immune responses, cell-migration and autophagy. (Johannes et. al 2018) There are now over 9319 publications on galectins in PubMed, with most, as mentioned above, about galectins-1 (>1989) and -3 (>4791). Evidence from literature suggests roles for galectins in e.g. fibrosis, inflammation and cancer (Dings et. al., Dubé-Delarosbil et. al 2017).
Galectin-1 is widely expressed in many cell types and tissues (www.proteinatlas.org) being involved in mechanisms such as apoptosis, adhesion and migration, cell transformation, invasion and metastasis immune escape and angiogenesis. Upregulation of galectin 1 has also been associated with cancer (Dings et. al. 2018), inflammation (Sundblad et. al., 2017) fibrotic disease (Kathiriya et. al 2017, Wu et. al. 2019 and Bennet et. al 2019) and diabetes (Drake et. al. 2022). Example of small molecule ligands including β-D-galactopyranoside were recently reviewed and exemplified in Blanchard et. al 2016 and Sethi et. al 2021).
Galectin-3 is widely expressed in many cell types and tissues (www.proteinatlas.org) being involved in mechanisms such as apoptosis, adhesion and migration, cell transformation, invasion and metastasis immune escape and angiogenesis. Upregulation of galectin 3 has also been associated with cancer, inflammation, neurodegenerative disease, fibrotic disease and diabetes (Dings et. al. 2018, Slack et. al. 2020, Li et. al. 2016) Example of small molecule ligands including β-D-galactopyranoside were recently reviewed and exemplified in Blanchard et. al 2014 and Sethi et. al 2021.
The compounds of the present invention are novel β-D-galactopyranose compounds that unexpectedly have shown high affinity for galectin-1 and/or -3 and are considered novel potent drug candidates.
In a first aspect the present invention relates to a D-galactopyranose compound of formula (1)
wherein
In second aspect the present invention concerns a β-D-galactopyranose compound of formula (1)
wherein
In an embodiment Het1 is selected from the group consisting of
In a further embodiment Het1 is formula 2
In a still further embodiment B1 is a pyrazolyl substituted with one or more groups selected from the group consisting of a) C1-4 alkyl optionally substituted with one or more of C1-6 alkyl, amino, CN, halogen, hydroxy, C1-6 alkoxy, carboxy, alkoxycarbonyl, H2NCO, b) R28—C1-6 alkyl, c) C3-6 cycloalkyl optionally substituted with one or more of C1-6 alkyl, amino, CN, halogen, or hydroxy, c) C2-4 alkenyl, d) C1-6 alkoxy, e) C1-6 alkylthio, f) C1-6 alkylsulfonyl, g) COOH or COOC1-4 alkyl h) (R31)(R32)N, i) C2-alkynyl, j) R28, k) halogen, l) cyano; wherein R28, R31 and R32 are as defined in the first aspect.
In a still further embodiment B1 is a pyrazolyl substituted with one or more groups selected from the group consisting of pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl, or indolyl; optionally substituted with a group selected from a) C1-6 alkyl optionally substituted with one or more of C1-6 alkyl, halogen, hydroxy, C1-6 alkoxy, carboxy, alkoxycarbonyl, H2NCO, b) R28-C1-6 alkyl, c) C3-6 cycloalkyl optionally substituted with one or more of C1-6 alkyl, halogen, or hydroxy, c) C1-6 alkenyl, d) C1-6 alkoxy, e) C1-6 alkylthio, f) C1-6 alkylsulfonyl, g) carbonyl substituted with any one of hydroxy, C1-6 alkoxy, C1-6 alkylNH, ((R29)(R30)N)C1-6 alkylNH, or (pyridinyl)C1-6 alkylNH, h) (R31)(R32)N, and j) R28;
In a further embodiment B1 is a pyrazolyl substituted with a phenyl optionally substituted with a group selected from methyl, CF3, and halogen.
In a still further embodiment B1 is
wherein the asterix * indicates the carbon atom of the pyrazol ring that is covalently attached to the galactopyranose,
wherein R4a, R5a, and R6a are independently selected from the group consisting of hydrogen, C1-4 alkyl, C2-4 alkenyl, halogen, cyano, COOH, COOC1-4 alkyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, benzothiazolyl, phenyl, or indolyl, provided that not all three of R4a, R5a, and R6a are hydrogen at the same time; wherein pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, benzothiazolyl, phenyl, or indolyl are optionally substituted with a group selected from cyano, nitro, OH, C2-alkynyl, halogen, C1-6 alkyl, halo-C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, halo-C1-6 alkoxy, C1-6 alkylthio, carboxy, C1-6 alkoxycarbonyl, CONH2.
In a still further embodiment B1 is
wherein the asterix * indicates the carbon atom of the pyrazol ring that is covalently attached to the galactopyranose,
wherein R4a, R5a, and R6a are independently selected from the group consisting of hydrogen, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl, or indolyl, provided that not all three of R4a, R5a, and R6a are hydrogen at the same time; optionally substituted with a group selected from a) C1-6 alkyl optionally substituted with one or more of C1-6 alkyl, halogen, hydroxy, C1-6 alkoxy, carboxy, alkoxycarbonyl, H2NCO, b) R28-C1-6 alkyl, c) C3-6 cycloalkyl optionally substituted with one or more of C1-6 alkyl, halogen, or hydroxy, c) C1-6 alkenyl, d) C1-6 alkoxy, e) C1-6 alkylthio, f) C1-6 alkylsulfonyl, g) carbonyl substituted with any one of hydroxy, C1-6 alkoxy, C1-6 alkylNH, ((R29)(R30)N)C1-6 alkylNH, or (pyridinyl)C1-6 alkylNH, h) (R31)(R32)N, and j) R28; wherein R28, R29, R30, R31 and R32 are as defined above. Typically, R4a is hydrogen, R5a is selected from hydrogen, halogen, C1-3 alkyl, COOH, COOC1-3 alkyl, C2-3 alkenyl, cyano and R6a is selected from a) a phenyl substituted with a group selected from methyl, CF3, and halogen; b) a pyridinyl substituted with a group selected from methyl, CF3, and halogen; or c) a benzothiazolyl substituted with a group selected from methyl, CF3, and halogen. In an alternative, R4a is hydrogen, R5a is hydrogen and R6a is a phenyl substituted with a group selected from methyl, CF3, and halogen.
In a still further embodiment R1 is selected from OC1-6 alkyl optionally substituted with one or more halogen, phenyl, phenyl substituted with one or more groups selected form OH and halogen, CN, OR37, NR38R39, and CONH2, wherein R37 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R40—CONH— wherein R40 is selected from C1-3 alkyl and cyclopropyl, R38 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R41—CONH— wherein R41 is selected from C1-3 alkyl and cyclopropyl, and R39 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R42—CONH— wherein R42 is selected from C1-3 alkyl and cyclopropyl.
In a further embodiment R1 is selected from OC1-6 alkyl optionally substituted with one or more halogen.
In a still further embodiment R1 is selected from OC1-3 alkyl.
In a further embodiment R1 is OH.
Preferably, the compound of formula (1) selected from any one of the group consisting of:
In a further embodiment, the compound of formula (1) selected from any one of the group consisting of:
In a further aspect the present invention relates to a compound of formula (1) for use as a medicine.
In a still further aspect, the present invention relates to a pharmaceutical composition comprising the compound of any one of the previous claims and optionally a pharmaceutically acceptable additive, such as a carrier and/or excipient.
In a further aspect the present invention relates to a compound of formula (1) of the present invention for use in a method for treating a disorder relating to the binding of a galectin-1 and/or -3 to a ligand in a mammal, such as a human.
In a further embodiment the disease or disorder is selected from the group consisting of inflammation, such as acute post myocardial infarctions (MI), acute coronary syndrome, acute stent occlusion, acute myocardial reperfusion injury, acute pneumonitidies, acute lung injury (ALI), acute kidney injury (AKI), acute hepatitis, acute on chronic liver failure, acute alcohol hepatitis, acute pancreatitis, acute uveitis, acute pancreatitis related liponecrosis, acute retinitis, acute nephritis, acute myocarditis, chronic autoimmune diseases in all organs, (e.g. lung, liver, kidney, heart, skin, muscle, gut), chronic bacterial infections, chronic viral related inflammation; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart, acute post-surgical ocular fibrosis, acute transplantation rejection of the kidney, heart, lung, liver, and pancreas, acute post explosion/improvised explosive devices, acute post toxic dust (such as dust from terror attack known as 9/11), acute chemical exposure, chronic lung fibrosis, interstitial lung fibrosis (IPF), Interstitial Lung Disease (ILD), Childhood ILD (ChILD); chronic liver fibrosis, chronic alcohol fibrosis, chronic viral fibrosis, chronic diabetic fibrosis, diabetic nephropathy, chronic glomerulonephritis, renal artery stenosis, endometriosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; scleroderma; systemic sclerosis; septic shock; cancers, such as carcinomas, sarcomas, leukemias and lymphomas, such as T-cell lymphomas; metastasising cancers; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, intestinal fibrosis, ankylosing spondylitis, systemic lupus erythematosus; metabolic disorders; coagulopathies, such as thrombosis proneness idiopathic (thrombophilia), autoimmune based thrombophilia, microthrombosis at multiorgan failure, COVID-19 related coagulopathy, thrombophilia in cancer disease; cardiovascular disorders, such as cardiac fibrosis, cardiac failure, left and right atrial fibrillation, atheromatosis, arterial inflammation, arterial calcification, aortic stenosis; heart disease; heart failure; aortic stenosis, atherosclerosis, pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; endocrine disorders, such as Addison, autoimmune hypophysitis; metabolic diseases such as diabetes; type 2 diabetes; insulin resistance; obesity; Diastolic HF; atrophic diseases in the brain, such as Alzheimer's and Parkinson's, atrophic diseases in the cerebellum, such as cerebellar atrophy, atrophic spinal diseases such as ALS; disorders related to transplantation in organs, such as anti-rejection prophylaxis, anti-acute rejection, anti-chronic rejection; acute burn; acute inflammatory reaction; chronic acute skin graft rejection; chronic scarring; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, pulmonary arterial hypertension, Rheumatoid disease associated interstitial lung disease RA-ILD, Systemic Sclerosis SSc-ILD, lung disease with fibrosis such as COPD (Chronic Obstructive Pulmonary Disease) and asthma; Otosclerosis, mesothelioma; post-surgery disorders, such as anti-keloid, anti-stricture, anti-adhesion, anti-thrombosis, fibrosis/scar reduction following cosmetic procedures; toxin exposure disorders, such as toxic hepatitis, cholera toxin related, mushroom toxin based acute renal failure, pertussis toxin, Aeromonas hydrophila enterotoxin, cadmium induced cardiac toxicity, Helicobacter O-antigen related toxicity, LPS based toxicity, Streptozotocin toxicity, asbestos exposure, Nephrogenic Systemic Fibrosis (Post Contrast Agents); Tissue injury, such as Spinal cord injury, Peripheral nerve repair; congenital hepatic fibrosis; hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis; liver disorders, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease, liver cirrhosis of various origins, such as alcoholic and non-alcoholic, autoimmune cirrhosis such as primary biliary cirrhosis and sclerosing cholangitis, virally induced cirrhosis, cirrhosis induced by genetic disease; Liver cancer, cholangiocarcinoma, biliary tract cancer; neurodegenerative disorders such as Parkinsons disease, Alzheimers disease, cognitive impairment, cerebrovascular diseases such as stroke, traumatic brain injury, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), peripheral nephropathy.
In a still further aspect the present invention relates to a method for treatment of a disease or disorder relating to the binding of a galectin-1 and/or -3 to a ligand in a mammal, such as a human, wherein a therapeutically effective amount of at least one compound of formula (1) of the present invention is administered to a mammal in need of said treatment.
In a further embodiment the disease or disorder is selected from the group consisting of inflammation, such as acute post myocardial infarctions (MI), acute coronary syndrome, acute stent occlusion, acute myocardial reperfusion injury, acute pneumonitidies, acute lung injury (ALI), acute kidney injury (AKI), acute hepatitis, acute on chronic liver failure, acute alcohol hepatitis, acute pancreatitis, acute uveitis, acute pancreatitis related liponecrosis, acute retinitis, acute nephritis, acute myocarditis, chronic autoimmune diseases in all organs, (e.g. lung, liver, kidney, heart, skin, muscle, gut), chronic bacterial infections, chronic viral related inflammation; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart, acute post-surgical ocular fibrosis, acute transplantation rejection of the kidney, heart, lung, liver, and pancreas, acute post explosion/improvised explosive devices, acute post toxic dust (such as dust from terror attack known as 9/11), acute chemical exposure, chronic lung fibrosis, interstitial lung fibrosis (IPF), Interstitial Lung Disease (ILD), Childhood ILD (ChILD); chronic liver fibrosis, chronic alcohol fibrosis, chronic viral fibrosis, chronic diabetic fibrosis, diabetic nephropathy, chronic glomerulonephritis, renal artery stenosis, endometriosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; scleroderma; systemic sclerosis; septic shock; cancers, such as carcinomas, sarcomas, leukemias and lymphomas, such as T-cell lymphomas; metastasising cancers; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, intestinal fibrosis, ankylosing spondylitis, systemic lupus erythematosus; metabolic disorders; coagulopathies, such as thrombosis proneness idiopathic (thrombophilia), autoimmune based thrombophilia, microthrombosis at multiorgan failure, COVID-19 related coagulopathy, thrombophilia in cancer disease; cardiovascular disorders, such as cardiac fibrosis, cardiac failure, left and right atrial fibrillation, atheromatosis, arterial inflammation, arterial calcification, aortic stenosis; heart disease; heart failure; aortic stenosis, atherosclerosis, pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; endocrine disorders, such as Addison, autoimmune hypophysitis; metabolic diseases such as diabetes; type 2 diabetes; insulin resistance; obesity; Diastolic HF; atrophic diseases in the brain, such as Alzheimer's and Parkinson's, atrophic diseases in the cerebellum, such as cerebellar atrophy, atrophic spinal diseases such as ALS; disorders related to transplantation in organs, such as anti-rejection prophylaxis, anti-acute rejection, anti-chronic rejection; acute burn; acute inflammatory reaction; chronic acute skin graft rejection; chronic scarring; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, pulmonary arterial hypertension, Rheumatoid disease associated interstitial lung disease RA-ILD, Systemic Sclerosis SSc-ILD, lung disease with fibrosis such as COPD (Chronic Obstructive Pulmonary Disease) and asthma; Otosclerosis, mesothelioma; post-surgery disorders, such as anti-keloid, anti-stricture, anti-adhesion, anti-thrombosis, fibrosis/scar reduction following cosmetic procedures; toxin exposure disorders, such as toxic hepatitis, cholera toxin related, mushroom toxin based acute renal failure, pertussis toxin, Aeromonas hydrophila enterotoxin, cadmium induced cardiac toxicity, Helicobacter O-antigen related toxicity, LPS based toxicity, Streptozotocin toxicity, asbestos exposure, Nephrogenic Systemic Fibrosis (Post Contrast Agents); Tissue injury, such as Spinal cord injury, Peripheral nerve repair; congenital hepatic fibrosis; hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis; liver disorders, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease, liver cirrhosis of various origins, such as alcoholic and non-alcoholic, autoimmune cirrhosis such as primary biliary cirrhosis and sclerosing cholangitis, virally induced cirrhosis, cirrhosis induced by genetic disease; Liver cancer, cholangiocarcinoma, biliary tract cancer; neurodegenerative disorders such as Parkinsons disease, Alzheimers disease, cognitive impairment, cerebrovascular diseases such as stroke, traumatic brain injury, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), peripheral nephropathy.
Another aspect of the present invention concerns combination therapy involving administering a compound of formula (1) of the present invention together with a therapeutically active compound different from the compound of formula (1) (interchangeable with “a different therapeutically active compound”). In one embodiment the present invention relates to a combination of a compound of formula (I) and a different therapeutically active compound for use in treatment of a disorder relating to the binding of a galectin-1/3 to a ligand in a mammal. Such disorders are disclosed below.
In an embodiment of the present invention, a therapeutically effective amount of at least one compound of formula (I) of the present invention is administered to a mammal in need thereof in combination with a different therapeutically active compound. In a further embodiment, said combination of a compound of formula (I) together with a different therapeutically active compound is administered to a mammal suffering from a disorder selected from the group consisting of inflammation; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer, such as carcinomas, sarcomas, leukemias and lymphomas, such as T-cell lymphomas; metastasising cancers; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases such as diabetes; type 2 diabetes; insulin resistens; obesity; Diastolic HF; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, mesothelioma; liver disorders, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease.
A non-limiting group of cancers given as examples of cancers, including both solid and liquid cancers, that may be treated, managed and/or prevented by administration of a compound of formula (1) in combination with a different therapeutically active compound is selected from: colon carcinoma, breast cancer, head and neck cancer, testis cancer, urothelial cancer, pancreatic cancer, ovarian cancer, prostate cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangeosarcoma, lymphangeoendothelia sarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystandeocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioblastomas, neuronomas, craniopharingiomas, schwannomas, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroama, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemias and lymphomas, acute lymphocytic leukemia and acute myelocytic polycythemia vera, multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease, acute nonlymphocytic leukemias, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's Disease, non-Hodgkin's lymphomas, rectum cancer, urinary cancers, uterine cancers, oral cancers, skin cancers, stomach cancer, brain tumors, liver cancer, laryngeal cancer, esophageal cancer, mammary tumors, childhood-null acute lymphoid leukemia (ALL), thymic ALL, B-cell ALL, acute myeloid leukemia, myelomonocytoid leukemia, acute megakaryocytoid leukemia, Burkitt's lymphoma, acute myeloid leukemia, chronic myeloid leukemia, and T cell leukemia, small and large non-small cell lung carcinoma, acute granulocytic leukemia, germ cell tumors, endometrial cancer, gastric cancer, cancer of the head and neck, chronic lymphoid leukemia, hairy cell leukemia and thyroid cancer.
In some aspects of the present invention, the administration of at least one compound of formula (I) of the present invention and at least one additional therapeutic agent demonstrates therapeutic synergy. In some aspects of the methods of the present invention, a measurement of response to treatment observed after administering both at least one compound of formula (I) of the present invention and the additional therapeutic agent is improved over the same measurement of response to treatment observed after administering either the at least one compound of formula (I) of the present invention or the additional therapeutic agent alone.
A further aspect of the present invention concerns combination therapy involving administering a compound of formula (I) of the present invention together with an anti-fibrotic compound different from the compound of formula (I) to a mammal in need thereof. In a further embodiment, such anti-fibrotic compound may be selected from the following non-limiting group of anti-fibrotic compounds: pirfenidone, nintedanib, simtuzumab (GS-6624, AB0024), BG00011 (STX100), PRM-151, PRM-167, PEG-FGF21, BMS-986020, FG-3019, MN-001, IW001, SAR156597, GSK2126458, PAT-1251 and PBI-4050.
A further aspect of the present invention concerns combination therapy involving administering a compound of formula (I) of the present invention together with an anti-cardiovascular compound different from the compound of formula (I) to a mammal in need thereof.
A still further aspect of the present invention concerns combination therapy involving administering a compound of formula (I) in combination with a further conventional cancer treatment such as chemotherapy and/or radiotherapy, and/or treatment with immunostimulating substances, and/or gene therapy, and/or treatment with antibodies and/or treatment using dendritic cells, to a mammal in need thereof.
In an embodiment the compound of formula (I) is administered together with at least one additional therapeutic agent selected from an antineoplastic chemotherapy agent. In a further embodiment, the antineoplastic chemotherapeutic agent is selected from: all-trans retinoic acid, Actimide, Azacitidine, Azathioprine, Bleomycin, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Irinotecan, Lenalidomide, Leucovorin, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Revlimid, Temozolomide, Teniposide, Thioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine and Vinorelbine. In one embodiment, a chemotherapeutic agent for use in the combination of the present agent may, itself, be a combination of different chemotherapeutic agents. Suitable combinations include FOLFOX and IFL. FOLFOX is a combination which includes 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. IFL treatment includes irinotecan, 5-FU, and leucovorin.
In a further embodiment of the present invention, the further conventional cancer treatment includes radiation therapy. In some embodiments, radiation therapy includes localized radiation therapy delivered to the tumor. In some embodiments, radiation therapy includes total body irradiation.
In other embodiments of the present invention the further cancer treatment is selected from the group of immunostimulating substances e.g. cytokines and antibodies. Such cytokines may be selected from the group consisting of, but not limited to: GM-CSF, type I IFN, interleukin 21, interleukin 2, interleukin 12 and interleukin 15. The antibody is preferably an immunostimulating antibody such as anti-CD40 or anti-CTLA-4 antibodies. The immunostimulatory substance may also be a substance capable of depletion of immune inhibitory cells (e.g. regulatory T-cells) or factors, said substance may for example be E3 ubiquitin ligases. E3 ubiquitin ligases (the HECT, RING and U-box proteins) have emerged as key molecular regulators of immune cell function, and each may be involved in the regulation of immune responses during infection by targeting specific inhibitory molecules for proteolytic destruction. Several HECT and RING E3 proteins have now also been linked to the induction and maintenance of immune self-tolerance: c-Cbl, Cbl-b, GRAIL, Itch and Nedd4 each negatively regulate T cell growth factor production and proliferation.
In some embodiments of the present invention the compound of formula (I) is administered together with at least one additional therapeutic agent selected from a checkpoint inhibitor. In some embodiments of the invention, the checkpoint inhibitor is acting on one or more of the following, non-limiting group of targets: CEACAM1, galectin-9, TIM3, CD80, CTLA4, PD-1, PD-L1, HVEM, BTLA, CD160, VISTA, B7-H4, B7-2, CD155, CD226, TIGIT, CD96, LAG3, GITF, OX40, CD137, CD40, IDO, and TDO. These are known targets and some of these targets are described in Melero et al., Nature Reviews Cancer (2015). Examples of check point inhibitors administered together with the compound of formula (1) are Anti-PD-1: Nivolumab, Pembrolizumab, Cemiplimab. Anti-PD-L1: Atezolizumab, Avelumab, Durvalumab and one Anti-CTLA-4: Ipilimumab. Each one of these check point inhibitors can be made the subject of an embodiment in combination with any one of the compounds of formula (1).
In some embodiments of the present invention the compound of formula (I) is administered together with at least one additional therapeutic agent selected from an inhibitor of indoleamine-2,3-dioxygenase (IDO).
In some embodiments of the present invention the compound of formula (I) is administered together with at least one additional therapeutic agent selected from one or more inhibitors of the CTLA4 pathway. In some embodiments, the inhibitor of the CTLA4 pathway is selected from one or more antibodies against CTLA4.
In some embodiments of the present invention the compound of formula (I) is administered together with at least one additional therapeutic agent selected from one or more inhibitors of the PD-1/PD-L pathway. In some embodiments, the one or more inhibitors of the PD-1/PD-L pathway are selected from one or more antibodies or antibody fragments against PD-1, PD-L1, and/or PD-L2, or other ways by which an anti-PD1 antibodies can be induced such as mRNA based introduction of genetic material which sets forth in-body production of anti-PD1 or anti-PDL1 antibodies or fragments of such antibodies.
In a still further aspect the present invention relates to a process of preparing a compound of formula II or a pharmaceutically acceptable salt or solvate thereof comprising the step a1 where A1, B1 and R1 are defined as above under formula 1;
a1) Reacting the compound of formula I with a compound of formula Het1-CC—H or Het1-CC-TMS or Het1-CC-TIPS in an inert solvent, such as DMF or acetonitrile, using a base, such as diisopropylethylamine or L-ascorbic acid sodium salt, catalyzed by a copper salt such as CuI or copper(II) sulfate, optionally using a reagent such as CsF or TBAF to provide a compound of the formula II.
In a still further aspect the present invention relates to a process of preparing a compound of formula IV or a pharmaceutically acceptable salt or solvate thereof comprising the step a2 where A1, B1 and R1 are defined as above under formula 1;
a2) Reacting a compound of formula III wherein X1 and X2 together form a protective group such as benzylidene in the presence of an acid, such as TFA or HCl, in an inert solvent, such as DCM, followed by neutralisation with a base, such as triethylamine, optionally at temperatures below room temperature, to give a compound of formula IV.
In a still further aspect the present invention relates to a process of preparing a compound of formula VI or a pharmaceutically acceptable salt or solvate thereof comprising the step a3 where B and R1 are defined as above under formula 1;
a3) Reacting a compound of formula V wherein X3 and X4 are protective groups such as boc-groups in the presence of an acid, such as TFA in an inert solvent, such as DCM, followed by neutralisation with a base, such as triethylamine, optionally at temperatures below room temperature, to give a compound of formula VI.
In a still further aspect the present invention relates to a process of preparing a compound of formula VIII or a pharmaceutically acceptable salt or solvate thereof comprising the step a4 where A1, R1 and R28 are defined as above under formula 1;
a4) Reacting a compound of formula VII wherein X5 and X6 together form a protective group such as benzylidene with either N,N-dimethylformamide dimethyl acetal or N,N-dimethylacetamide dimethyl acetal at elevated temperature followed by removal of solvents. The residues could be further reacted with R28—NHNH2 in a solvent such as ethanol in the presence of acid such as HCl to give a product of formula VIII wherein X7 is either a hydrogen or a methyl.
In a still further aspect the present invention relates to a process of preparing a compound of formula X or a pharmaceutically acceptable salt or solvate thereof comprising the step a5 where A1, R1 and R28 are defined as above under formula 1;
a5) Reacting a compound of formula IX wherein X8 is an alkyl such as ethyl with a base such as sodium hydroxide in a solvent mixture such as methanol/water/THF to give a compound of formula X.
In a still further aspect the present invention relates to a process of preparing a compound of formula XII or a pharmaceutically acceptable salt or solvate thereof comprising the step a6 where A1, R1 and R28 are defined as above under formula 1;
a6) Reacting a compound of the formula XI wherein X9 is an alkenyl group with hydrogen in the presence of a suitable catalyst such as platinum(IV) oxide in an inert solvent such as THF to give a compound of formula XII wherein X10 is an alkyl group.
In a still further aspect the present invention relates to a process of preparing a compound of formula XIX or a pharmaceutically acceptable salt or solvate thereof comprising the steps a7-a12 where A1 is defined as above under formula 1;
a7) Reacting a compound of the formula XIII wherein X11-X14 is a protective group such as acetate, with a cyanide reagent such as trimethylsilyl cyanide in the presence of a reagent such as boron trifluoride diethyl etherate in an inert solvent such as nitromethane at 0° C. to give a compound of formula XIV.
a8) Reacting a compound of the formula XIV wherein X11-X13 is a protective group such as acetate with acetyl chloride in methanol giving a product which is further reacted with benzaldehyde dimethylacetal in the presence of D(+)-10-camphorsulfonic acid to give a compound of formula XV, wherein X11 and X12 together form a protective group such as benzylidene and X13 is a hydrogen. Optionally the compound of formula XV wherein X11 and X12 together form a protective group such as benzylidene and X13 is a hydrogen could be reacted further with an alkyl halide such as iodomethane in the presence of a base such as cesium carbonate in a solvent such as DMF to give a compound of formula XV wherein X11 and X12 together form a protective group such as benzylidene and X13 is an alkyl group such as methyl.
a9) Reacting a compound of the formula XV with a base such as lithium hydroxide in a mixture of solvents such as water/THF to give a compound of formula XVI.
a10) Reacting a compound of the formula XVI with N, O-dimethylhydroxylamine in the presence of a coupling reagent such as HATU and an organic base such as DIPEA in a solvent such as DMF to give a compound of formula XVII. Optionally the compound of formula XVII wherein X13 is a hydrogen could be reacted further with an alkyl halide such as iodomethane in the presence of a base such as cesium carbonate in a solvent such as DMF to give a compound of formula XVII wherein X13 is an alkyl group such as methyl. Optionally the compound of formula XVII wherein X13 is a hydrogen could be reacted further with bromo(methoxy)methane in the presence of silver(I) oxide and sodium iodide in a solvent such as DMF to give a compound of formula XVII wherein X13 is a MOM group.
a11) Reacting a compound of formula XVII wherein X13 is defined as above with methylmagnesium bromide in an inert solvent such as THF to give a compound of formula XVIII.
a12) Reacting a compound of formula XVIII wherein X13 is defined as above with a compound of formula Het1-CC—H or Het1-CC-TMS in an inert solvent, such as DMF or acetonitrile, using a base, such as DIPEA or L-ascorbic acid sodium salt, catalyzed by a copper salt such as CuI or copper(II) sulfate, optionally using a reagent such as CsF to provide a compound of formula XIX.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXII or a pharmaceutically acceptable salt or solvate thereof comprising the step a13 where R1 and R28 are defined as above under formula 1;
a13) Reacting a compound of formula XX wherein X and X together form a protective group such as benzylidene with diethyl oxalate using a base, such as lithium diisopropylamide in an inert solvent, such as THF at temperatures ranging from −78° C. to room temperature followed by removal of solvents. The residues could be further reacted with R28—NHNH2 in a solvent such as ethanol in the presence of acid such as acetic acid to give a product of formula XXI wherein X14 and X15 either together form a protective group such as benzylidene or are hydrogens.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXIII or a pharmaceutically acceptable salt or solvate thereof comprising the step a14 where A1, R1 and R28 are defined as above under formula 1;
a14) Reacting a compound of formula XXII wherein X16 and X17 together form a protective group such as benzylidene with a compound of formula Het1-CC—H or Het1-CC-TMS in an inert solvent, such as DMF or acetonitrile, using a base, such as DIPEA or L-ascorbic acid sodium salt, catalyzed by a copper salt such as CuI or copper(II) sulfate, optionally using a reagent such as CsF to provide a compound of formula XXIII.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXVI or a pharmaceutically acceptable salt or solvate thereof comprising the steps a15-a16 where A1, R1 and R28 are defined as above under formula 1;
a15) Reacting a compound of formula XXIV wherein X18 and X19 together form a protective group such as benzylidene with N,N-dimethylformamide dimethyl acetal at elevated temperature to give a compound of formula XXV.
a16) Reacting a compound of formula XXV with R28—NHNH2 in a solvent such as ethanol in the presence of acid such as HCl to give a compound of formula XXVI.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXI or a pharmaceutically acceptable salt or solvate thereof comprising the steps a17-a20 where R1 and R28 are defined as above under formula 1_
a17) Reacting a compound of formula XXVII wherein X20 and X21 together form a protective group such as benzylidene with a base such as sodium hydroxide in a solvent mixture such as methanol/water/THF to give a compound of formula XXVIII.
a18) Reacting a compound of formula XXVIII with diphenylphosphoryl azide and 2-trimethylsilylethanol using a base such as triethylamine in an inert solvent such as 1,4-dioxane to give a compound of formula XXIX.
a19) Reacting a compound of formula XXIX with TBAF in an inert solvent such as THF to give a compound of formula XXX.
a20) Reacting a compound of formula XXX with a cupper salt, such as CuCl or CuBr and a reagent, such as pentyl nitrite, in the presence of a reagent, such as LiCl or CuBr2, at 0° C. to give a compound of formula XXXI wherein X22 is a halide such as chlorine or bromine.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXI or a pharmaceutically acceptable salt or solvate thereof comprising the step a21 where A1, R1 and R28 are defined as above under formula 1;
a21) Reacting a compound of formula XXXII wherein X23 and X24 together form a protective group such as benzylidene and X25 is a halide such as bromine with a compound of the formula L1-X26, wherein L1 is defined as a boronic acid, borinatester, tinalkyl or zincalkyl suitable for cross-coupling reactions such as Suzuki, Stille or Negishi couplings in the presence of a catalyst such as Pd(PPh3)4 or Pd(dppf)Cl2 in a suitable solvent such as 1,4-dioxane/water optionally in the presence of a base such as K2CO3, optionally at elevated temperature to give a compound of formula XXXIII wherein X26 is an alkenyl group.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXVI or a pharmaceutically acceptable salt or solvate thereof comprising the steps a22-a23 where R1 and R28 are defined as above under formula 1;
a22) Reacting a compound of formula XXXII wherein X27 and X28 together form a protective group such as benzylidene with ammonia in a suitable solvent such as methanol optionally at elevated temperature to give a compound of formula XXXV.
a23) Reacting a compound of formula XXXV with pyridine and trifluoroacetic anhydride in an inert solvent such as THF to give a compound of formula XXXVI.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXIX or a pharmaceutically acceptable salt or solvate thereof comprising the steps a24-a25 where R28 is defined as above under formula 1;
a24) Reacting a compound of the formula XXXVII with acetic acid in the presence of iron at elevated temperature to give a compound of formula XXXVIII.
a25) Reacting a compound of the formula XXXVIII with sodium nitrite in the presence of HCl and acetic acid in water solution to give a product that is reacted with tin(II)chloride to give a compound of formula XXXIX.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXXI or a pharmaceutically acceptable salt or solvate thereof comprising the step a26 where R28 is defined as above under formula 1;
a26) Reacting a compound of formula XXXX wherein L is a leaving group such as a halide such as bromine with methyl 2,2-difluoro-2-fluorosulfonylacetate in the presence of a copper salt such as CuI in an inert solvent such as DMF optionally at elevated temperature to give a compound of formula XXXXI.
In a still further aspect the present invention relates to a process of preparing a compound of formula Het1-CC—H or Het1-CC-TMS comprising the step a27 wherein Het1 is defined as above under formula 1;
a27) Reacting a compound of formula Het1-L3 wherein L3 is defined as a leaving group such as chlorine or bromine with trimethylsilaneacetylene using a palladium catalyst such as bis(triphenylphosphine)palladium(II)-chloride, CuI and a base such as DIPEA in an inert solvent, such as THF, to give a compound of formula Het1-CC—H or Het1-CC-TMS.
In a still further aspect the present invention relates to a process of preparing a compound of formula XXXXIV comprising the step a28 wherein R1a, R2a and R3a are as defined under formula 11 of Het1 which is defined as above under formula 1;
a28) Reacting a compound of formula XXXXII with a compound of formula XXXXIII wherein L4 is defined as a halide such as bromine or iodine and X29 is either a hydrogen or a protective group such as triisopropylsilane in the presence of CuI and a base such as Cs2CO3 in an inert solvent, such as 1,4-diaxane and PEG400, to give a compound of formula XXXXIV.
The present compounds of formula (1) differ from prior art compounds particularly in that the pyranose ring is β-D-galactopyranose. It is important to emphasize that alpha and beta anomers are very different isomers and it is by no means considered to be obvious to the skilled person to expect same or similar activity of both anomers. Consequently, alpha and beta anomers do not in general posses the same activity, and this is common knowledge to the skilled person. The compounds of the present invention are novel β-D-galactopyranose compounds that unexpectedly have high affinity galectin-1 and/or 3 inhibitors.
In a broad aspect the present invention concerns a β-D-galactopyranose compound of formula (1)
wherein
In an embodiment Het1 is a five membered heteroaromatic ring selected from the group consisting of formulas 2, 3, 4, 5, 9, 10 and 11, wherein the asterix * indicates the carbon atom of the heteroaromatic ring that is covalently attached to the triazole group in formula A1:
wherein R1a, R2a, R3a, R2 to R11, R27, R35 and R36 are independently selected from H; halogen; OH; CN; SH; S—C1-6 alkyl; C1-6 alkyl, optionally substituted with a F; cyclopropyl, optionally substituted with a F; O-cyclopropyl optionally substituted with a F; OC1-6 alkyl optionally substituted with a F; NR24R25, wherein R24 is selected from H and C1-6 alkyl, and R25 is selected from H, C1-3 alkyl, and C(═O)R26, wherein R26 is selected from H, and C1-6 alkyl; C(═O)NR24aR25a, wherein R24a is selected from H and C1-6 alkyl, and R25a is selected from H, C1-3 alkyl, and C(═O)R26a, wherein R26a is selected from H, and C1-6 alkyl; C(═O)OR24bR25b, wherein R24b is selected from H and C1-6 alkyl, and R25b is selected from H, C1-3 alkyl, and C(═O)R26b, wherein R26b is selected from H, and C1-6 alkyl.
In another embodiment Het1 is a six membered heteroaromatic ring selected from the group consisting of formulas 6, 7 and 8, wherein the asterix * indicates the carbon atom of the heteroaromatic ring that is covalently attached to the triazole group in formula A1:
wherein R12 to R23 are independently selected from H; halogen; OH; CN; SH; S—C1-6 alkyl; C1-6 alkyl, optionally substituted with a F; O-cyclopropyl optionally substituted with a F; OC1-6 alkyl optionally substituted with a F; NR24R25, wherein R24 is selected from H and C1-6 alkyl, and R25 is selected from H, C1-3 alkyl, and C(═O)R26, wherein R26 is selected from H, and C1-6 alkyl; C(═O)NR24aR25a, wherein R24a is selected from H and C1-6 alkyl, and R25a is selected from H, C1-3 alkyl, and C(═O)R26a, wherein R26a is selected from H, and C1-6 alkyl; C(═O)OR24bR25b, wherein R24b is selected from H and C1-6 alkyl, and R25b is selected from H, C1-3 alkyl, and C(═O)R26b, wherein R26b is selected from H, and C1-6 alkyl.
In a further embodiment Het1 is
wherein R2 is selected from the group consisting of hydrogen, methyl, OH and halogen;
R3 is selected from the group consisting of hydrogen, C1-6 alkyl and halogen.
In a still further embodiment Het1 is formula 2 wherein R2 is selected from the group consisting of hydrogen, methyl, OH, F and Cl; and R3 is selected from the group consisting of hydrogen, methyl, F and Cl.
In a further embodiment Het1 is formula 2 wherein R2 is selected from the group consisting of hydrogen, C1-3 alkyl, e.g. methyl, and halogen, e.g. Cl; and R3 is selected from the group consisting of hydrogen, C1-3 alkyl, e.g. methyl, and halogen, e.g. Cl. In one embodiment both R2 and R3 are hydrogen. In another embodiment one of R2 and R3 is hydrogen and the other is selected from the group consisting of hydrogen, C1-3 alkyl, and halogen.
In a further embodiment Het1 is
wherein
In a further embodiment Het1 is formula 3 wherein
In a further embodiment Het1 is
wherein
In a further embodiment Het1 is
In a further embodiment Het1 is formula 11 wherein R1a is hydrogen; R2a is hydrogen; and R3a is selected from the group consisting of halogen, such as Cl.
In a further embodiment B1 is a pyrazol substituted with one to three groups selected from a) C1-6 alkyl optionally substituted with one or more of C1-6 alkyl, amino, CN, halogen, hydroxy, C1-6 alkoxy, carboxy, alkoxycarbonyl, H2NCO, b) R28—C1-6 alkyl, c) C3-6 cycloalkyl optionally substituted with one or more of C1-6 alkyl, amino, CN, halogen, or hydroxy, c) C1-6 alkenyl, d) C1-6 alkoxy, e) C1-6 alkylthio, f) C1-6 alkylsulfonyl, g) carbonyl substituted with any one of hydroxy, C1-6 alkoxy, C1-6 alkylNH, ((R29)(R30)N)C1-6 alkylNH, or (pyridinyl)C1-6 alkylNH, h) (R31)(R32)N, i) C2-alkynyl, and j) phenyl, naphthalinyl, biphenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, quinoxainyl, indolyl, indazolyl, benzimidazolyl, benzisoxazolyl, benzisothiazolyl, benzoxazolyl, benzothiazolyl, benzodioxolyl, dihydrobenzodioxinyl, dihydroquinolinonyl, dihydrobenzothiophene-2,2-dioxide, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, or thiadiazolyl; optionally substituted with one or more substituents selected from the group consisting of cyano, nitro, OH, C2-alkynyl, halogen, C1-6 alkyl, halo-C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, halo-C1-6 alkoxy, C1-6 alkylthio, carboxy, C1-6 alkoxycarbonyl, CONH2, and (R33)(R34)N; or b) (C1-6 alkyl-SO2)phenyl, (C1-6 alkyl SO2)(halo)phenyl, (aminoSO2)phenyl, (di-C1-6 alkylaminoSO2)phenyl, ((C1-6 alkyl-NHSO2)—C1-6 alkyl)phenyl, (pyrrolyl)phenyl, (imidazolyl)phenyl, (oxazolyl)phenyl, (tetrazolyl)phenyl, ((pyridinyl)methyl)phenyl, phenoxyphenyl, (benzyloxy)phenyl, ((methyl)thiazolyl)-phenyl, (thiazolyl)-benzenesulfamido, ((methyl)thiadiazolyl)benzenesulfamido, (methyl)-benzothiazolonyl, or fluoropyrazolopyrimidinyl;
wherein
In a further embodiment B1 is a pyrazolyl substituted with a phenyl optionally substituted with a group selected from methyl, CF3, and halogen.
In a still further embodiment B1 is
wherein the asterix * indicates the carbon atom of the pyrazol ring that is covalently attached to the galactopyranose,
wherein R4a is selected from the group consisting of hydrogen, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl, or indolyl; optionally substituted with a group selected from a) C1-6 alkyl optionally substituted with one or more of C1-6 alkyl, halogen, hydroxy, C1-6 alkoxy, carboxy, alkoxycarbonyl, H2NCO, b) R28-C1-6 alkyl, c) C3-6 cycloalkyl optionally substituted with one or more of C1-6 alkyl, halogen, or hydroxy, c) C1-6 alkenyl, d) C1-6 alkoxy, e) C1-6 alkylthio, f) C1-6 alkylsulfonyl, g) carbonyl substituted with any one of hydroxy, C1-6 alkoxy, C1-6 alkylNH, ((R29)(R30)N)C1-6 alkylNH, or (pyridinyl)C1-6 alkylNH, h) (R31)(R32)N, and j) R28; wherein R28, R29, R30, R31 and R32 are as defined above,
Typically, R4a is hydrogen, R5a is hydrogen and R6a is benzothiazolyl substituted with a methyl.
In a further embodiment R1 is a) OC1-6 alkyl optionally substituted with one or more halogen, phenyl, phenyl substituted with one or more groups selected form OH and halogen, CN, OR37, NR38R39, and CONH2, wherein R37 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R40—CONH— wherein R40 is selected from C1-3 alkyl and cyclopropyl, R38 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R41—CONH— wherein R41 is selected from C1-3 alkyl and cyclopropyl, and R39 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R42—CONH— wherein R42 is selected from C1-3 alkyl and cyclopropyl,
In a still further embodiment R1 is OC1-6 alkyl optionally substituted with one or two halogen, phenyl, phenyl substituted with one or more groups selected form OH and halogen, CN, OR37, NR38R39, and CONH2, wherein R37 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R40—CONH— wherein R40 is selected from C1-3 alkyl and cyclopropyl, R38 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R41—CONH— wherein R41 is selected from C1-3 alkyl and cyclopropyl, and R39 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R42—CONH— wherein R42 is selected from C1-3 alkyl and cyclopropyl. Typically, R1 is selected from OC1-6 alkyl optionally substituted with one or more halogen, such as R1 is selected from OC1-3 alkyl, e.g. methoxy.
In a further embodiment R1 is b) branched OC3-6 alkyl optionally substituted with one or more halogen, CN, OR43, NR44R45, and CONH2, wherein R43 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R46—CONH— wherein R46 is selected from C1-3 alkyl and cyclopropyl, R44 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R47—CONH— wherein R47 is selected from C1-3 alkyl and cyclopropyl, and R45 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R48—CONH— wherein R48 is selected from C1-3 alkyl and cyclopropyl.
In a still further embodiment R1 is c) cyclic OC3-6 alkyl optionally substituted with one or more halogen, CN, OR49, NR50R51, and CONH2, wherein R49 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R52—CONH— wherein R52 is selected from C1-3 alkyl and cyclopropyl, R50 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R53—CONH— wherein R53 is selected from C1-3 alkyl and cyclopropyl, and R51 is selected from the group consisting of H, CN, a halogen, methyl optionally substituted with a F, OCH3 optionally substituted with a F, OCH2CH3 optionally substituted with a F, OH, and R54—CONH— wherein R54 is selected from C1-3 alkyl and cyclopropyl.
Preferably, the compound of formula (1) selected from any one of the compounds of examples 1-39; or a pharmaceutically acceptable salt or solvate thereof.
The skilled person will understand that it may be necessary to adjust or change the order of steps in the processes a1-a28, and such change of order is encompassed by the aspects of the process as described above in the reaction schemes and accompanying description of the process steps.
Furthermore, the skilled person will understand that the processes described above and hereinafter the functional groups of intermediate compounds may need to be protected by protecting groups.
Functional groups that it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include optionally substituted and/or unsaturated alkyl groups (e.g. methyl, allyl, benzyl or tert-butyl), trialkyl silyl or diarylalkylsilyl groups (e.g. t-butyldimethylsilyl, t-butyldipheylsilyl or trimethylsilyl), AcO(acetoxy), TBS(t-butyldimethylsilyl), TMS(trimethylsilyl), PMB (p-methoxybenzyl), and tetrahydropyranyl. Suitable protecting groups for carboxylic acid include (C1-6)-alkyl or benzyl esters. Suitable protecting groups for amino include t-butyloxycarbonyl, benzyloxycarbonyl, 2-(trimethylsilyl)-ethoxy-methyl or 2-trimethylsilylethoxycarbonyl (Teoc). Suitable protecting groups for S include S—C(═N)NH2, TIPS.
The protection and deprotection of functional groups may take place before or after any reaction in the above-mentioned processes.
Furthermore the skilled person will appreciate, that, in order to obtain compounds of the invention in an alternative, and on some occasions more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual reactions may be performed at a different stage in the overall route (i.e. substituents may be added to and/or chemical transformations performed upon, different intermediates to those mentioned hereinbefore in conjunction with a particular reaction). This may negate, or render necessary, the need for protecting groups.
In a still further embodiment the compound (1) is on free form. “On free form” as used herein means a compound of formula (1), either an acid form or base form, or as a neutral compound, depending on the substitutents. The free form does not have any acid salt or base salt in addition. In one embodiment the free form is an anhydrate. In another embodiment the free form is a solvate, such as a hydrate.
In a further embodiment the compound of formula (1) is a crystalline form. The skilled person may carry out tests in order to find polymorphs, and such polymorphs are intended to be encompassed by the term “crystalline form” as used herein.
Whenever a “compound of formula (1)” is used herein it means the compound of formula (1) in any form incl the free form or as a salt thereof, such as a pharmaceutically acceptable salt thereof, unless otherwise indicated herein or clearly contradicted by context.
When the compounds and pharmaceutical compositions herein disclosed are used for the above treatment, a therapeutically effective amount of at least one compound is administered to a mammal in need of said treatment.
The term “C1-x alkyl” as used herein means an alkyl group containing 1-x carbon atoms, e.g. C1-5 or C1-6, such as methyl, ethyl, propyl, butyl, pentyl or hexyl.
The term “branched C3-6 alkyl” as used herein means a branched alkyl group containing 3-6 carbon atoms, such as isopropyl, isobutyl, tert-butyl, isopentyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl.
The term “C3-x cycloalkyl” as used herein means a cyclic alkyl group containing 3-x carbon atoms, e.g. C3-6 or C3-7, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 1-methylcyclopropyl.
The term “C5-7 cycloalkyl” as used herein means a cyclic alkyl group containing 5-7 carbon atoms, such as cyclopentyl, cyclohexyl, or cycloheptyl.
The term “Oxo” as used herein means an oxygen atom with double bonds, also indicated as ═O.
The term “CN” as used herein means a nitril (interchangeable with cyano).
The term “halogen” as used herein means Cl, F, Br or I.
The term “halo-C1-6 alkyl” as used herein means one or more halogens linked to a C1-6 alkyl, such as CF3, CH(Cl)CHF2.
The term “C1-6 alkoxy” as used herein means an oxygen linked to a C1-6 alkyl, such as methoxy or ethoxy.
The term “C1-6 alkylthio” as used herein means a sulphur linked to a C1-6 alkyl, such as thiomethoxy or thioethoxy.
The term “halo-C1-6 alkoxy” as used herein means one or more halogens linked to a C1-6 alkoxy, such as CH(F2)CH(Br)O—.
The term “C1-6 alkoxycarbonyl” as used herein means a C1-6 alkoxy linked to a carbonyl, such as methoxycarbonyl (CH2OC(═O)).
The term “a five or six membered heteroaromatic ring” as used herein means one five membered heteroaromatic ring or one six membered heteroaromatic ring. The five membered heteroaromatic ring contains 5 ring atoms of which one to four are heteroatoms selected from N, O, and S. The six membered heteroaromatic ring contains 6 ring atoms of which one to five are heteroatoms selected from N, O and S. Examples include thiophene, furan, pyran, pyrrole, imidazole, pyrazole, isothiazole, isooxazole, pyridine, pyrazine, pyrimidine and pyridazine. When such heteroaromatic rings are substituents they are termed thiophenyl, furanyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isooxazolyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl. Also included are oxazoyl, thiazoyl, thiadiazoly, oxadiazoyl, and pyridonyl.
The term “a heterocycle, such as heteroaryl or heterocycloalkyl” as used herein means a heterocycle consisting of one or more 3-7 membered ring systems containing one or more heteroatoms and wherein such ring systems may optionally be aromatic. The term “a heteroaryl” as used herein means a mono or bicyclic aromatic ringsystem containing one or more heteroatoms, such as 1-10, e.g. 1-6, selected from O, S, and N, including but not limited to oxazolyl, oxadiazolyl, thiophenyl, thiadiazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridonyl, pyrimidonyl, quinolinyl, azaquionolyl, isoquinolinyl, azaisoquinolyl, quinazolinyl, azaquinazolinyl, bensozazoyl, azabensoxazoyl, bensothiazoyl, or azabensothiazoyl. The term “a heterocycloalkyl” as used herein means a mono or bicyclic 3-7 membered alifatic heterocycle containing one or more heteroatoms, such as 1-7, e.g. 1-5, selected from O, S, and N, including but not limited to piperidinyl, tetrahydropyranyl, tetrahydrothipyranyl, or piperidonyl.
The term “treatment” and “treating” as used herein means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. The treatment may either be performed in an acute or in a chronic way. The patient to be treated is preferably a mammal; in particular, a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
The term “a therapeutically effective amount” of a compound of formula (1) of the present invention as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
In a still further aspect, the present invention relates to a pharmaceutical composition comprising the compound of formula (1) and optionally a pharmaceutically acceptable additive, such as a carrier or an excipient.
As used herein “pharmaceutically acceptable additive” is intended without limitation to include carriers, excipients, diluents, adjuvant, colorings, aroma, preservatives etc. that the skilled person would consider using when formulating a compound of the present invention in order to make a pharmaceutical composition.
The adjuvants, diluents, excipients and/or carriers that may be used in the composition of the invention must be pharmaceutically acceptable in the sense of being compatible with the compound of formula (1) and the other ingredients of the pharmaceutical composition, and not deleterious to the recipient thereof. It is preferred that the compositions shall not contain any material that may cause an adverse reaction, such as an allergic reaction. The adjuvants, diluents, excipients and carriers that may be used in the pharmaceutical composition of the invention are well known to a person skilled within the art.
As mentioned above, the compositions and particularly pharmaceutical compositions as herein disclosed may, in addition to the compounds herein disclosed, further comprise at least one pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier. In some embodiments, the pharmaceutical compositions comprise from 1 to 99% by weight of said at least one pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier and from 1 to 99% by weight of a compound as herein disclosed. The combined amount of the active ingredient and of the pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier may not constitute more than 100% by weight of the composition, particularly the pharmaceutical composition.
In some embodiments, only one compound as herein disclosed is used for the purposes discussed above.
In some embodiments, two or more of the compounds as herein disclosed are used in combination for the purposes discussed above.
The composition, particularly pharmaceutical composition comprising a compound set forth herein may be adapted for oral, intravenous, topical, intraperitoneal, nasal, buccal, sublingual, or subcutaneous administration, or for administration via the respiratory tract in the form of, for example, an aerosol or an air-suspended fine powder. Therefore, the pharmaceutical composition may be in the form of, for example, tablets, capsules, powders, nanoparticles, crystals, amorphous substances, solutions, transdermal patches or suppositories.
Further embodiments of the process are described in the experimental section herein, and each individual process as well as each starting material constitutes embodiments that may form part of embodiments.
The above embodiments should be seen as referring to any one of the aspects (such as ‘method for treatment’, ‘pharmaceutical composition’, ‘compound for use as a medicament’, or ‘compound for use in a method’) described herein as well as any one of the embodiments described herein unless it is specified that an embodiment relates to a certain aspect or aspects of the present invention.
All references, including publications, patent applications and patents, cited herein are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.
All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
The terms “a” and “an” and “the” and similar referents as used in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also pro-vide a corresponding approximate measurement, modified by “about,” where appropriate).
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise indicated. No language in the specification should be construed as indicating any element is essential to the practice of the invention unless as much is explicitly stated.
The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability and/or enforceability of such patent documents.
The term “and/or” as used herein is intended to mean both alternatives as well as each of the alternatives individually. For instance, the expression “xxx and/or yyy” means “xxx and yyy”; “xxx”; or “yyy”, all three alternatives are subject to individual embodiments.
The description herein of any aspect or embodiment of the invention using terms such as “comprising”, “having”, “including” or “containing” with reference to an element or elements is intended to provide support for a similar aspect or embodiment of the invention that “consists of”, “consists essentially of”, or “substantially comprises” that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
The present invention is further illustrated by the following examples that, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realizing the invention indiverse forms thereof.
The affinity of Example 1-39 for galectins were determined by a fluorescence anisotropy assay where the compound was used as an inhibitor of the interaction between galectin and a fluorescein tagged saccharide probe as described Sarme, P., Kahl-Knutsson, B., Huflejt, M., Nilsson, U. J., and Leffler H. (2004) Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions. Anal. Biochem. 334: 36-47, (Sarme et al., 2004) and Monovalent interactions of Galectin-1 By Salomonsson, Emma; Larumbe, Amaia; Tejler, Johan; Tullberg, Erik; Rydberg, Hanna; Sundin, Anders; Khabut, Areej; Frejd, Torbjorn; Lobsanov, Yuri D.; Rini, James M.; et al, From Biochemistry (2010), 49(44), 9518-9532, (Salomonsson et al., 2010).
Nuclear Magnetic Resonance (NMR) spectra were recorded on a 400 MHz Bruker AVANCE III 500 instrument or a Varian instrument at 400 MHz, at 25° C. Chemical shifts are reported in ppm (d) using the residual solvent as internal standard. Peak multiplicities are expressed as follow: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplet; q, quartet; m, multiplet; br s, broad singlet. LC-MS were acquired on an Agilent 1200 HPLC coupled with an Agilent MSD mass spectrometer operating in ES (+) ionization mode. Column: XBridge C18 (4.6×50 mm, 3.5 μm) or SunFire C18 (4.6×50 mm, 3.5 μm). Solvent A water+0.1% TFA and solvent B Acetonitrile+0.1% TFA or solvent A water (10 mM Ammonium hydrogen carbonate) and solvent B Acetonitrile. Wavelength: 254 nM. Alternatively, LC-MS were acquired on an Agilent 1100 HPLC coupled with an Agilent MSD mass spectrometer operating in ES (+) ionization mode. Column: Waters symmetry 2.1×30 mm C18 or Chromolith RP-18 2×50 mm. Solvent A water+0.1% TFA and solvent B Acetonitrile+0.1% TFA. Wavelength 254 nm.
Preparative HPLC was performed on a Gilson 215. Flow: 25 mL/min Column: XBrige prep C18 10 μm OBD (19×250 mm) column. Wavelength: 254 nM. Solvent A water (10 mM Ammonium hydrogen carbonate) and solvent B Acetonitrile. Alternatively, preparative HPLC were acquired on a Gilson system. Flow: 15 ml/min Column: kromasil 100-5-C18 column. Wavelength: 220 nm. Solvent A water+0.1% TFA and solvent B Acetonitrile+0.1% TFA.
The following abbreviations are used
When naming examples and intermediates with aryl groups connected directly to C1 of the galactose unit the following methodology has been used. The highest priority has been given to the aryl furthest away from the galactose C1, regardless of IUPAC rules.
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (62 mg, 0.14 mmol) in DMF (2 mL) 2-(4-chlorothiazol-2-yl)ethynyltrimethylsilane (59.8 mg, 0.28 mmol), copper(II) sulfate pentahydrate (34.6 mg, 0.14 mmol) and (+)-sodium L-ascorbate (27.4 mg, 0.14 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to give the title compound (45.2 mg, 55%). ESI-MS m/z calcd for [C22H19Cl2F3N6O4S] [M+H]+: 591.1; found: 591.0 1H NMR (400 MHz, Methanol-d4) δ 8.76 (s, 1H), 7.94 (d, J=8.4 Hz, 1H), 7.82 (d, J=8.4 Hz, 1H), 7.77-7.76 (m, 2H), 7.47 (s, 1H), 6.88 (d, J=2.0 Hz, 1H), 4.94 (dd, J=10.4, 2.8 Hz, 1H), 4.71-4.30 (m, 1H), 4.19 (d, J=9.2 Hz, 1H), 4.08 (d, J=2.4 Hz, 1H), 3.74-3.57 (m, 3H), 2.95 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (62 mg, 0.14 mmol) in DMF (2 mL) trimethyl(2-thiazol-2-ylethynyl)silane (50.2 mg, 0.28 mmol), copper(II) sulfate pentahydrate (34.6 mg, 0.14 mmol) and (+)-sodium L-ascorbate (27.4 mg, 0.14 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to give the title compound (39.5 mg, 51%). ESI-MS m/z calcd for [C22H20ClF3N6O4S] [M+H]+: 557.1; found: 557.2. 1H NMR (400 MHz, Methanol-d4) δ 8.73 (s, 1H), 7.94 (d, J=8.4 Hz, 1H), 7.90 (d, J=3.6 Hz, 1H), 7.87-7.68 (m, 3H), 7.64 (d, J=3.2 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 4.94 (dd, J=10.4, 2.8 Hz, 1H), 4.72-4.26 (m, 1H), 4.20 (d, J=9.2 Hz, 1H), 4.09 (d, J=2.4 Hz, 1H), 3.84-3.55 (m, 3H), 2.95 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (70 mg, 0.16 mmol) in DMF (3 mL) trimethyl-[2-(5-methylthiazol-2-yl)ethynyl]silane (61.1 mg, 0.31 mmol), copper(II) sulfate pentahydrate (39.0 mg, 0.16 mmol) and (+)-sodium L-ascorbate (31.0 mg, 0.16 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to give the title compound (49.3 mg, 55%). ESI-MS m/z calcd for [C23H22ClF3N6O4S] [M+H]+: 571.1; found: 571.0. 1H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.67 (d, J=1.6 Hz, 1H), 7.60-7.47 (m, 2H), 6.78 (d, J=2.0 Hz, 1H), 4.83 (dd, J=10.4, 2.8 Hz, 1H), 4.58-4.20 (m, 1H), 4.10 (d, J=8.4 Hz, 1H), 3.98 (d, J=2.0 Hz, 1H), 3.72-3.46 (m, 3H), 2.84 (s, 3H), 2.44 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (45 mg, 0.10 mmol) in DMF (3 mL) trimethyl-[2-(4-methylthiazol-2-yl)ethynyl]silane (58.9 mg, 0.30 mmol), copper(II) sulfate pentahydrate (25.1 mg, 0.10 mmol) and (+)-sodium L-ascorbate (19.9 mg, 0.10 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to give the title compound (26.3 mg, 46%). ESI-MS m/z calcd for [C23H22ClF3N6O4S] [M+H]+: 571.1; found: 571.2. 1H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.78-7.44 (m, 3H), 7.09 (s, 1H), 6.78 (d, J=2.0 Hz, 1H), 4.84 (dd, J=10.4, 2.8 Hz, 1H), 4.57-4.19 (m, 1H), 4.10 (d, J=9.2 Hz, 1H), 3.99 (d, J=2.4 Hz, 1H), 3.67-3.47 (m, 3H), 2.85 (s, 3H), 2.38 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (40 mg, 0.092 mmol) in DMF (2 mL) trimethyl(2-thiazol-2-ylethynyl)silane (50.2 mg, 0.28 mmol), copper(II) sulfate pentahydrate (23 mg, 0.092 mmol) and (+)-sodium L-ascorbate (18.3 mg, 0.092 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to afford the title compound (25.7 mg, 51%). ESI-MS m/z calcd for [C21H18ClF3N6O4S] [M+H]+: 543.1; found: 542.8. 1H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.89 (d, J=3.2 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.78-7.74 (m, 1H), 7.73 (d, J=1.6 Hz, 1H), 7.63 (d, J=3.2 Hz, 1H), 6.77 (d, J=1.6 Hz, 1H), 4.88-4.83 (m, 1H), 4.74-4.53 (m, 1H), 4.20 (d, J=9.2 Hz, 1H), 4.12 (d, J=2.8 Hz, 1H), 3.70-3.53 (m, 3H).
To a solution of 1-{5-{3-{4-[2-(di-tert-butoxycarbonylamino)thiazol-4-yl]-1H-1,2,3-triazol-1-yl}-3-deoxy-β-D-galactopyranosyl}-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (66 mg, 0.087 mmol) in DCM (6 mL) TFA (0.20 mL) was added and the mixture was stirred overnight at rt. Et3N (0.5 mL) was added at 0° C.
The mixture was concentrated and was dissolved in DMF (3 mL). The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 m/min, UV 254) to afford the title compound (29.8 mg, 61%). ESI-MS m/z calcd for [C21H19ClF3N7O4S] [M+H]+: 558.1; found: 557.7. 1H NMR (400 MHz, Methanol-d4) δ 8.24 (s, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.78-7.70 (m, 2H), 6.94 (s, 1H), 6.76 (d, J=2.0 Hz, 1H), 4.79 (dd, J=10.4, 2.8 Hz, 1H), 4.71-4.50 (m, 1H), 4.18 (d, J=8.4 Hz, 1H), 4.10 (d, J=2.8 Hz, 1H), 3.70-3.53 (m, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (60 mg, 0.14 mmol) in DMF (2 mL) 4-(2-trimethylsilylethynyl)thiazol-2-ol (54.6 mg, 0.28 mmol), copper(II) sulfate pentahydrate (34.5 mg, 0.14 mmol) and (+)-sodium L-ascorbate (27.4 mg, 0.14 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (31.3 mg, 40%). ESI-MS m/z calcd for [C21H18ClF3N6O5S] [M+H]+: 559.1; found: 558.8. 1H NMR (400 MHz, Methanol-d4) δ 8.28 (s, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.71 (d, J=8.8 Hz, 1H), 7.69-7.64 (m, 2H), 6.64 (s, 1H), 6.58 (s, 1H), 4.72 (d, J=9.2 Hz, 1H), 4.63-4.38 (m, 1H), 4.09 (d, J=7.2 Hz, 1H), 4.00 (s, 1H), 3.53 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (60 mg, 0.14 mmol) in DMF (3 mL) 2-(3-chloropyrazol-1-yl)ethynyl(triisopropyl)silane (58.7 mg, 0.21 mmol), copper(II) sulfate pentahydrate (34.5 mg, 0.14 mmol), (+)-sodium L-ascorbate (27.4 mg, 0.14 mmol) and tetrabutylammonium fluoride (0.14 mL, 1 M in THF, 0.14 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (28.7 mg, 37%). ESI-MS m/z calcd for [C21H18Cl2F3N7O4] [M+H]+: 560.1; found: 559.8. 1H NMR (400 MHz, Methanol-d4) δ 8.24 (s, 1H), 8.14 (d, J=2.4 Hz, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.68-7.52 (m, 2H), 6.67 (d, J=1.6 Hz, 1H), 6.41 (d, J=2.4 Hz, 1H), 4.71 (dd, J=10.4, 2.8 Hz, 1H), 4.63-4.43 (m, 1H), 4.09 (d, J=9.2 Hz, 1H), 4.02 (d, J=2.4 Hz, 1H), 3.58-3.47 (m, 3H).
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-(methoxymethyl)-D-glycero-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(5-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-(methoxymethyl)-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(5-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-(methoxymethyl)-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(5-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-deoxy-4-O-methyl-5-[4-(2-thiazol-2-yl)-1H-1,2,3-triazol-1-yl]-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-3-D-galactopyranosyl)-3-ethoxycarbonyl-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (62 mg, 0.12 mmol) in DMF (3 mL) 2-(4-chlorothiazol-2-yl)ethynyltrimethylsilane (51.5 mg, 0.24 mmol), copper(II) sulfate pentahydrate (29.8 mg, 0.12 mmol) and (+)-sodium L-ascorbate (23.6 mg, 0.12 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (44 mg, 56%). ESI-MS m/z calcd for [C25H23Cl2F3N6O6S] [M+H]+: 663.1; found: 663.1. 1H NMR (400 MHz, Methanol-d4) δ 8.78 (s, 1H), 7.96 (d, J=8.4 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.86-7.52 (m, 1H), 7.47 (s, 1H), 7.34 (s, 1H), 4.97 (dd, J=10.4, 2.8 Hz, 1H), 4.65-4.55 (m, 1H), 4.40 (q, J=7.2 Hz, 2H), 4.24-4.20 (m, 1H), 4.07 (br s, 1H), 3.69-3.60 (m, 3H), 3.01-2.91 (m, 3H), 1.40 (t, J=7.2 Hz, 3H).
To a solution of 1-{5-{3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-ethoxycarbonyl-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (35 mg, 0.053 mmol) in MeOH/THF/H2O (6.00 mL, 1:1:1) NaOH (20.0 mg, 0.500 mmol) was added and the mixture was stirred 2 h at rt. Acetic acid (0.1 mL) was added. The mixture was concentrated and purified by prep HPLC [MeCN/H2O (0.1% TFA), X-Select 10 μm 19*250 mm, 20 m/min, UV 254] to afford the title compound (10.9 mg, 33%). ESI-MS m/z calcd for [C23H19Cl2F3N6O6S][M+H]+: 635.0; found: 635.0. 1H NMR (400 MHz, Methanol-d4) δ 8.79 (br s, 1H), 7.95 (d, J=8.8 Hz, 1H), 7.87-7.57 (m, 2H), 7.47 (s, 1H), 7.29 (s, 1H), 4.96 (dd, J=10.0, 2.0 Hz, 1H), 4.62-4.53 (m, 1H), 4.22-4.18 (m, 1H), 4.09-4.06 (m, 1H), 3.71-3.60 (m, 3H), 3.00-2.91 (m, 3H).
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(5-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-(methoxymethyl)-
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-methyl-1-N,N-dimethylamino-
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-methyl-1l-N,N-dimethylamino-
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-methyl-1-N,N-dimethylamino-
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-methyl-1-N,N-dimethylamino-
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-(methoxymethyl)-1-N,N-dimethylamino-
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-chloro-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (69 mg, 0.097 mmol) in DCM (4 mL) TFA (0.2 mL) was added and the mixture was stirred overnight at rt. Et3N (1 mL) was added at 0° C. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 m/min, UV 254) to afford the title compound (43.1 mg, 71%). ESI-MS m/z calcd for [C22H18Cl3F3N6O4S] [M+H]+: 625.0; found: 625.1. 1H NMR (400 MHz, Methanol-d4) δ 8.76 (s, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.92-7.62 (m, 2H), 7.47 (s, 1H), 6.86 (s, 1H), 4.95 (dd, J=10.4, 2.8 Hz, 1H), 4.52-4.37 (m, 1H), 4.17 (d, J=9.2 Hz, 1H), 4.07 (d, J=2.0 Hz, 1H), 3.69-3.62 (m, 3H), 2.97 (s, 3H).
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-bromo-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (71 mg, 0.094 mmol) in DCM (6 mL) TFA (0.2 mL) was added and the mixture was stirred overnight at rt. Et3N (1 mL) was added at 0° C. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 m/min, UV 254) to afford the title compound (25.6 mg, 41%). ESI-MS m/z calcd for [C22H18BrCl2F3N6O4S] [M+H]+: 669.0; found: 668.9. 1H NMR (400 MHz, Methanol-d4) δ 8.75 (s, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.92-7.61 (m, 2H), 7.47 (s, 1H), 6.93 (s, 1H), 4.94 (dd, J=10.4, 3.2 Hz, 1H), 4.55-4.35 (m, 1H), 4.18 (d, J=8.8 Hz, 1H), 4.07 (d, J=2.0 Hz, 1H), 3.69-3.60 (m, 3H), 2.97 (s, 3H).
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-(1-methylethenyl)-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (19 mg, 0.026 mmol) in DCM (5 mL) TFA (0.2 mL) was added and the mixture was stirred overnight at rt. Et3N (0.5 mL) was added at 0° C. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 mL/min, UV 254) to afford the title compound (9.3 mg, 56%). ESI-MS m/z calcd for [C25H23Cl2F3N6O4S] [M+H]+: 631.1; found: 631.2. 1H NMR (400 MHz, Methanol-d4) δ 8.77 (s, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.83-7.71 (m, 2H), 7.47 (s, 1H), 7.05 (s, 1H), 5.64 (s, 1H), 5.18 (s, 1H), 4.94 (dd, J=10.4, 2.8 Hz, 1H), 4.53-4.37 (m, 1H), 4.16 (d, J=9.2 Hz, 1H), 4.08 (d, J=2.4 Hz, 1H), 3.72-3.63 (m, 3H), 2.97 (s, 3H), 2.12 (s, 3H).
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-isopropyl-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (36 mg, 0.050 mmol) in DCM (3 mL) TFA (0.15 mL) was added and the mixture was stirred overnight at rt. Et3N (0.5 mL) was added at 0° C. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 mL/min, UV 254) to afford the title compound (8.07 mg, 26%). ESI-MS m/z calcd for [C25H25Cl2F3N6O4S] [M+H]+: 633.1; found: 633.3. 1H NMR (400 MHz, Methanol-d4) δ 8.75 (s, 1H), 7.92 (d, J=8.8 Hz, 1H), 7.91-7.65 (m, 2H), 7.47 (s, 1H), 6.74 (s, 1H), 4.92 (dd, J=10.2, 2.8 Hz, 1H), 4.53-4.37 (m, 1H), 4.13 (d, J=9.6 Hz, 1H), 4.07 (d, J=2.8 Hz, 1H), 3.72-3.61 (m, 3H), 3.06-2.94 (m, 4H), 1.31 (dd, J=7.2, 1.2 Hz, 6H).
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-ethenyl-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (33 mg, 0.047 mmol) in DCM (5 mL) TFA (0.2 mL) was added and the mixture was stirred overnight at rt. Et3N (0.5 mL) was added at 0° C. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 mL/min, UV 254) to afford the title compound (13 mg, 45%). ESI-MS m/z calcd for [C24H21Cl2F3N6O4S] [M+H]+: 617.1; found: 617.2. 1H NMR (400 MHz, Methanol-d4) δ 8.76 (s, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.83-7.62 (m, 2H), 7.47 (s, 1H), 7.06 (s, 1H), 6.71 (dd, J=17.6, 11.2 Hz, 1H), 5.92 (dd, J=17.6, 1.2 Hz, 1H), 5.42 (dd, J=11.2, 1.2 Hz, 1H), 4.94 (dd, J=10.8, 3.2 Hz, 1H), 4.53-4.37 (m, 1H), 4.15 (d, J=9.2 Hz, 1H), 4.08 (d, J=2.4 Hz, 1H), 3.72-3.63 (m, 3H), 2.97 (s, 3H).
To a solution of 1-{5-{3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-ethenyl-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (10 mg, 0.016 mmol) in MeOH (10 mL) platinum(IV) oxide (4.05 mg, 0.018 mmol) was added and the mixture was stirred 5 h at rt under hydrogen atmosphere. The mixture was filtered through a celite pad and concentrated. The residue was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 m/min, UV 254) to afford the title compound (2.6 mg, 26%). ESI-MS m/z calcd for [C24H23Cl2F3N6O4S] [M+H]+: 619.1; found: 619.2. 1H NMR (400 MHz, Methanol-d4) δ 8.75 (s, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.81-7.65 (m, 2H), 7.47 (s, 1H), 6.72 (s, 1H), 4.92 (dd, J=10.4, 2.8 Hz, 1H), 4.51-4.35 (m, 1H), 4.13 (d, J=9.2 Hz, 1H), 4.07 (d, J=2.4 Hz, 1H), 3.70-3.60 (m, 3H), 2.97 (s, 3H), 2.71 (q, J=7.6 Hz, 2H), 1.29 (t, J=7.6 Hz, 3H).
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1l-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-3-cyano-11H-1,2-pyrazol-1l-yl}-5-chloro-2-(trifluoromethyl)benzene (33 mg, 0.047 mmol) in DCM (3 mL) TFA (0.2 mL) was added and the mixture was stirred overnight at rt. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 mL/min, UV 254) to afford the title compound (9.4 mg, 33%). ESI-MS m/z calcd for [C23H18Cl2F3N7O4S] [M+H]+: 616.1; found: 616.1. 1H NMR (400 MHz, Methanol-d4) δ 8.78 (s, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.96-7.64 (m, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 4.98 (dd, J=10.4, 2.8 Hz, 1H), 4.54-4.49 (m, 1H), 4.29-4.24 (m, 1H), 4.07 (s, 1H), 3.69-3.59 (m, 3H), 2.94 (s, 3H).
To a solution of 4,8-anhydro-7,9-O-benzylidene-6-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-6-deoxy-5-O-methyl-1-N,N-dimethylamino-
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (22 mg, 0.049 mmol) in DMF (2 mL) 4-(2-trimethylsilylethynyl)thiazol-2-amine (14.5 mg, 0.074 mmol), copper(II) sulfate pentahydrate (12.3 mg, 0.049 mmol) and (+)-sodium L-ascorbate (9.7 mg, 0.049 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (7.3 mg, 26%). ESI-MS m/z calcd for [C22H21ClF3N7O4S] [M+H]+: 572.1; found: 572.1 1H NMR (400 MHz, Methanol-d4) δ 8.40 (br s, 1H), 7.95-7.75 (m, 4H), 6.97 (br s, 1H), 6.85 (d, J=2.0 Hz, 1H), 4.96-4.92 (m, 1H), 4.60-4.31 (m, 1H), 4.18 (d, J=9.2 Hz, 1H), 4.07 (s, 1H), 3.68-3.61 (m, 3H), 2.92 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-3-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (22 mg, 0.049 mmol) in DMF (2 mL) 4-(2-trimethylsilylethynyl)thiazol-2-ol (14.5 mg, 0.074 mmol), copper(II) sulfate pentahydrate (12.3 mg, 0.049 mmol) and (+)-sodium L-ascorbate (9.7 mg, 0.049 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (9.7 mg, 35%). ESI-MS m/z calcd for [C22H20ClF3N6O5S] [M+H]+: 573.1; found: 573.1 1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.83-7.50 (m, 3H), 6.83 (d, J=1.6 Hz, 1H), 6.70 (s, 1H), 4.92-4.89 (m, 1H), 4.53-4.37 (m, 1H), 4.19 (d, J=9.2 Hz, 1H), 4.06 (d, J=2.4 Hz, 1H), 3.69-3.60 (m, 3H), 2.91 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-4,5-dichloro-2-(trifluoromethyl)benzene (20 mg, 0.042 mmol) in DMF (1.5 mL) 4-(2-trimethylsilylethynyl)thiazol-2-ol (9.0 mg, 0.046 mmol), copper(II) sulfate pentahydrate (10.4 mg, 0.042 mmol) and (+)-sodium L-ascorbate (8.2 mg, 0.042 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (7.35 mg, 29%). ESI-MS m/z calcd for [C22H19Cl2F3N6O5S] [M+H]+: 607.1; found: 607.1 1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 8.14 (s, 1H), 7.91-7.76 (m, 2H), 6.82 (d, J=2.0 Hz, 1H), 6.70 (s, 1H), 4.91 (dd, J=10.4, 2.4 Hz, 1H), 4.43-4.23 (m, 2H), 4.05 (d, J=2.4 Hz, 1H), 3.67-3.61 (m, 3H), 2.91 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-β-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-bromo-4-fluoro-2-(trifluoromethyl)benzene (21 mg, 0.041 mmol) in DMF (1.5 mL) 4-(2-trimethylsilylethynyl)thiazol-2-ol (9 mg, 0.046 mmol), copper(II) sulfate pentahydrate (10.4 mg, 0.042 mmol) and (+)-sodium L-ascorbate (8.2 mg, 0.042 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (2.65 mg, 10%). ESI-MS m/z calcd for [C22H19BrF4N6O5S] [M+H]+: 635.0; found: 635.0 1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 8.05-7.71 (m, 3H), 6.81 (d, J=2.0 Hz, 1H), 6.70 (s, 1H), 4.92-4.90 (m, 1H), 4.52-4.21 (m, 2H), 4.05 (d, J=2.4 Hz, 1H), 3.67-3.61 (m, 3H), 2.91 (s, 3H).
To a solution of 1-[5-(3-azido-3-deoxy-2-O-methyl-3-D-galactopyranosyl)-1H-1,2-pyrazol-1-yl]-5-chloro-2-(trifluoromethyl)benzene (30 mg, 0.067 mmol) in DMF (2 mL) trimethyl(2-thiazol-4-ylethynyl)silane (36.4 mg, 0.020 mmol), copper(II) sulfate pentahydrate (16.7 mg, 0.067 mmol) and (+)-sodium L-ascorbate (13.3 mg, 0.067 mmol) were added and the mixture was stirred overnight at rt. The mixture was filtered, and the filtrate was purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μm 19*250 mm, 20 mL/min, UV 254) to afford the title compound (14.9 mg, 40%). ESI-MS m/z calcd for [C22H20ClF3N6O4S] [M+H]+: 557.1; found: 557.1 1H NMR (400 MHz, Methanol-d4) δ 8.87-8.56 (m, 1H), 8.23-7.31 (m, 6H), 6.87 (d, J=1.6 Hz, 1H), 4.95-4.93 (m, 1H), 4.62-4.32 (m, 1H), 4.20-4.17 (m, 1H), 4.10 (br s, 1H), 3.70-3.61 (m, 3H), 2.94 (s, 3H).
To a solution of 1-{-aminocarbonyl-5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-D-galactopyranosyl}-1H-1,2-pyrazol-1-yl}-5-chloro-2-(trifluoromethyl)benzene (29 mg, 0.040 mmol) in DCM (3 mL) TFA (0.15 mL) was added and the mixture was stirred overnight at rt. The mixture was concentrated and purified by prep HPLC (MeCN/H2O (10 mmol/L NH4HCO3), X-Select 10 μM 19*250 mm, 20 mL/min, UV 254) to afford the title compound (13.0 mg, 51%). ESI-MS m/z calcd for [C23H20Cl2F3N7O4S] [M+H]+: 634.1; found: 634.1. 1H NMR (400 MHz, Methanol-d4) δ 8.78 (s, 1H), 7.95 (d, J=8.4 Hz, 1H), 7.94-7.64 (m, 2H), 7.47 (s, 1H), 7.25 (s, 1H), 4.96 (dd, J=10.4, 2.8 Hz, 1H), 4.54-4.42 (m, 1H), 4.22 (d, J=9.2 Hz, 1H), 4.07 (d, J=2.8 Hz, 1H), 3.69-3.62 (m, 3H), 2.96 (s, 3H).
To a solution of 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-β-D-galactopyranoside (10.0 g, 26.8 mmol) and trimethylsilyl cyanide (6.70 mL, 53.6 mmol) in nitromethane (100 mL) under argon at 0° C. boron trifluoride diethyl etherate (3.31 mL, 26.8 mmol) was added and the mixture was stirred 5 h at rt. The mixture was concentrated and purified by column chromatography (PE/EtOAc=5/1-2/1, Silica-CS 80 g, 30 m/min, silica gel, UV 254) to give the product (7.40 g, 81%). ESI-MS m/z calcd for [C13H16N4O7][M+NH4]+: 358.1; found: 358.1. 1H NMR (400 MHz, CDCl3) δ 5.52-5.41 (m, 2H), 4.25 (d, J=10.0 Hz, 1H), 4.16-4.08 (m, 1H), 4.07-4.00 (m, 1H), 3.92-3.83 (m, 1H), 3.59 (dd, J=10.0, 3.2 Hz, 1H), 2.19 (s, 6H), 2.06 (s, 3H).
To a solution of 2,4,6-tri-O-acetyl-3-azido-3-deoxy-β-D-galactopyranosyl cyanide (7.40 g, 21.7 mmol) in MeOH (100 mL) at 0° C. acetyl chloride (8.535 g, 109 mmol) was added and the mixture was stirred overnight at 65° C. The mixture was concentrated, and the residue was dissolved in DMF (10 mL). Benzaldehyde dimethylacetal (9.918 g, 65.2 mmol) followed by D(+)-10-camphorsulfonic acid (1.009 g, 4.34 mmol) were added and the mixture was stirred 3 h at 50° C. under reduced pressure. The mixture was poured into water (30 mL) and extracted with EtOAc (3×30 mL). The combined organic phases were washed with brine, concentrated and purified by column chromatography (PE/EtOAc=5/1-1/1, Silica-CS 40 g, 30 mL/min, silica gel, UV 254) to give the product (4.00 g, 55%). ESI-MS m/z calcd for [C15H17N3O6] [M+NH4]+: 353.1; found: 353.1. 1H NMR (400 MHz, CDCl3) δ 7.55-7.45 (m, 2H), 7.42-7.30 (m, 3H), 5.58 (s, 1H), 4.45-4.34 (m, 2H), 4.26 (d, J=2.8 Hz, 1H), 4.06 (dd, J=12.8, 2.0 Hz, 1H), 3.89 (d, J=9.6 Hz, 1H), 3.84 (s, 3H), 3.52 (d, J=1.2 Hz, 1H), 3.50-3.46 (m, 1H), 3.41 (dd, J=10.4, 3.6 Hz, 1H).
To a solution of methyl 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-
To a stirred solution of 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-
To a solution of 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-1-C—(N-methoxy-N-methyl)-aldehydo-
To a solution of 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-3-O-methyl-1-C—(N-methoxy-N-methyl)-aldehydo-
A solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-D-glycero-L-manno-2-octulose (540 mg, 1.62 mmol) in N,N-dimethylformamide dimethyl acetal (5.0 mL) was stirred 16 h at 80° C. The mixture was concentrated to dryness and the residue was dissolved in EtOH (10 mL). [5-Chloro-2-(trifluoromethyl)phenyl]hydrazine (469 mg, 2.23 mmol) and concentrated HCl (0.2 mL) were added and the mixture was stirred 2 h at 80° C. The mixture was concentrated and purified by column chromatography (PE/EA=10/1˜1/2, Silica-CS 12 g, 20 m/min, silica gel, UV 254) to afford the product (300 mg, 38%). ESI-MS m/z calcd for [C17H17ClF3N5O4] [M+H]+: 448.1; found: 447.8. 1H NMR (400 MHz, Methanol-d4) δ 7.90 (d, J=8.4 Hz, 1H), 7.79 (d, J=8.4 Hz, 1H), 7.74 (d, J=2.0 Hz, 1H), 7.73 (br s, 1H), 6.76 (d, J=2.0 Hz, 1H), 4.02-3.54 (m, 5H), 3.45-3.27 (m, 5H).
To a solution of 2-bromo-5-methylthiazole (0.55 g, 3.09 mmol) in THF (15 mL) Et3N (1.72 mL, 12.4 mmol), bis(triphenylphosphine)palladium(II) chloride (108 mg, 0.15 mmol), ethynyl(trimethyl)silane (607 mg, 6.18 mmol) and CuI (58.8 mg, 0.31 mmol) were added and the mixture was stirred overnight at 50° C. The mixture was concentrated, the residue was dissolved in EtOAc and washed with water and brine. The organic phase was dried over Na2SO4, concentrated, and purified by column chromatography (PE/EA=1/0˜10/1, Silica-CS 12 g, 20 m/min, silica gel, UV 254) to afford the product (160 mg, 27%). 1H NMR (400 MHz, Chloroform-d) δ 7.44 (d, J=0.8 Hz, 1H), 2.48 (d, J=1.2 Hz, 3H), 0.27 (s, 9H).
To a solution of 2-bromo-4-methylthiazole (300 mg, 1.68 mmol) in THF (5 mL) ethynyl(trimethyl)silane (248 mg, 2.53 mmol), CuI (16 mg, 0.084 mmol) and bis(triphenylphosphine)palladium(II) chloride (59.1 mg, 0.084 mmol) and Et3N (0.47 mL, 3.37 mmol) were added and the mixture was stirred 2 h at 60° C. under a nitrogen atmosphere. The mixture was diluted with water (20 mL) and extracted with EA (3×20 mL). The organic phases were washed with brine, dried over MgSO4, concentrated, and purified by column chromatography (PE/EA=20/1˜10/1, Silica-CS 40 g, 50 m/min, silica gel, UV 254) to afford the product (225 mg, 68%). 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 2.45 (s, 3H), 0.26 (s, 9H).
To a solution of 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-1-C—(N-methoxy-N-methyl)-aldehydo-
To a cooled (0° C.) solution of 2,6-anhydro-4-azido-5,7-O-benzylidene-4-deoxy-3-O-(methoxymethyl)-1-C—(N-methoxy-N-methyl)-aldehydo-
A solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-(methoxymethyl)-
To a solution of 4-(2-trimethylsilylethynyl)thiazol-2-amine (2.00 g, 10.2 mmol) in DCM (50 mL) di-tert-butyl dicarbonate (4.45 g, 20.4 mmol), Et3N (5.68 mL, 40.8 mmol) and 4-(dimethylamino)pyridine (12.4 mg, 1.02 mmol) were added and the mixture was stirred 5 h at rt. Water (100 mL) was added, and the mixture was extracted with diethyl ether (3×100 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, evaporated, and purified by column chromatography (PE/EtOAc=1/0˜10/1, Silica-CS 40 g, 40 mL/min, silica gel, UV 254) to give the product (3.60 g, 89%). ESI-MS m/z calcd for [C18H28N2O4SSi] [M+H]+: 397.2; found: 397.3. 1H NMR (400 MHz, CDCl3) δ 7.25-7.18 (m, 1H), 1.45 (d, J=2.8 Hz, 18H), 0.18 (d, J=2.8 Hz, 9H).
To a solution of 1-[5-(3-azido-3-deoxy-β-
A solution of 3-chloro-1H-pyrazole (150 mg, 1.46 mmol), CuI (14 mg, 0.073 mmol), cesium carbonate (572 mg, 1.76 mmol) and 2-bromoethynyl(triisopropyl)silane (765 mg, 2.93 mmol) in 1,4-dioxane (2 mL) and PEG400 (400 mg) was stirred 4 h at 70° C. The mixture was filtered through a plug of celite, concentrated and purified by chromatography (SiO2, PE/EtOAc) to afford the product (68 mg, 16%). ESI-MS m/z calcd for [C14H23ClN2Si] [M+H]+: 283.1; found: 283.1.
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-(methoxymethyl)-
To a solution of 2-bromo-5-chlorothiazole (1.0 g, 5.0 mmol) in THF (30.0 mL) Pd(PPh3)2Cl2 (177 mg, 0.25 mmol), CuI (48 mg, 0.25 mmol), (trimethyl)silylacetylene (1.49 g, 15 mmol) and Et3N (2.1 mL, 15 mmol) were added and the mixture was stirred 4 h at 50° C. The mixture was concentrated, water (50 mL) was added, and the solution was extracted with DCM (2×50 mL). The combined organic phases were washed with brine, dried over Na2SO4, evaporated, and purified by column chromatography (EtOAc/PE=0˜1/10, Silica-CS 40 g, 40 mL/min, silica gel, UV 254) to afford the product (565 mg, 52%). 1H NMR (400 MHz, Chloroform-d) δ 7.08 (s, 1H), 0.27 (s, 9H).
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-(methoxymethyl)-
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-
To a solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-
ESI-MS m/z calcd for [C27H25ClF3N5O6] [M+H]+: 608.1; found: 608.3. 1H NMR (400 MHz, Chloroform-d) δ 7.68-7.35 (m, 8H), 7.17-7.12 (m, 1H), 5.54 (s, 1H), 4.46-4.40 (m, 2H), 4.24-4.15 (m, 2H), 4.03-3.62 (m, 3H), 3.46-3.27 (m, 5H), 1.40 (t, J=7.2 Hz, 3H).
ESI-MS m/z calcd for [C20H21ClF3N5O6] [M+H]+: 520.1; found: 520.2. 1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, J=8.8 Hz, 1H), 7.89-7.61 (m, 2H), 7.21 (s, 1H), 4.39 (q, J=7.2 Hz, 2H), 4.02-3.93 (m, 2H), 3.77-3.55 (m, 3H), 3.45-3.35 (m, 5H), 1.39 (t, J=7.2 Hz, 3H).
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-methyl-
To a solution of 1,2-dichloro-4-nitro-5-(trifluoromethyl)benzene (1.10 g, 4.23 mmol) in acetic acid (20 mL) iron (709 mg, 12.7 mmol) was added and the mixture was stirred 4 h at 80° C. The mixture was filtered, concentrated, and purified by column chromatography (EtOAc/PE=1/10-2/1, Silica-CS 40 g, 50 mL/min, silica gel, UV 254) to afford the product (833 mg, 86%). 1H NMR (400 MHz, Chloroform-d) δ 7.48 (s, 1H), 6.86 (s, 1H), 4.03 (br s, 2H).
To a solution of 4,5-chloro-2-(trifluoromethyl)aniline (833 mg, 3.62 mmol) in acetic acid (3 mL) concentrated HCl (3 mL) was added and the mixture was cooled to −5° C. A solution of NaNO2 (300 mg, 4.35 mmol) in water (2 mL) was added and the mixture was stirred 1 h at 0° C. A solution of tin(II) chloride dihydrate (1.79 g, 7.95 mmol) in concentrated HCl (3 mL) was added slowly at 0° C. The mixture was warmed to rt and stirred 3 h. The mixture was basified to pH=10 by addition of NaOH (1M). The mixture was extracted with EtOAc (2×50 mL). The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (DCM/PE=0/1˜4/1, Silica-CS 40 g, 50 mL/min, silica gel, UV 254) to afford the product (356 mg, 40%). ESI-MS m/z calcd for [C7H5Cl2F3N2] [M+H]+: 245.0; found: 245.1. 1H NMR (400 MHz, Chloroform-d) δ 7.53 (s, 1H), 7.48 (s, 1H), 5.85 (s, 1H), 3.66 (s, 2H).
To a cooled (0° C.) solution of 4-bromo-1-chloro-2-fluorobenzene (10.0 g, 47.7 mmol) and NH4NO3 (5.73 g, 71.6 mmol) in DCM (350 mL) trifluoroacetic anhydride (46.5 mL, 334 mmol) was added over 15 min. The mixture was stirred 15 min at 0° C. then 2 h at rt. The reaction was quenched with saturated aq NaHCO3 (560 mL) and the phases were separated. The aqueous phase was extracted with DCM and then EtOAc. The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/7, Silica-CS 80 g, 50 m/min, silica gel, UV 254) to afford the product (4.2 g, 35%). 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J=6.8 Hz, 1H), 8.21 (d, J=8.8 Hz, 1H).
To a solution of 1-bromo-4-chloro-5-fluoro-2-nitrobenzene (4.20 g, 16.5 mmol) in DMF (40 mL) methyl 2,2-difluoro-2-fluorosulfonylacetate (6.64 g, 33.0 mmol) and CuI (3.14 g, 16.5 mmol) were added and the mixture was stirred 2 h at 80° C. The reaction was quenched with saturated aq NaHCO3 (200 mL) and extracted with EtOAc (2×100 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/7, Silica-CS 80 g, 50 mL/min, silica gel, UV 254) to afford the product (3.7 g, 92%). 1H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J=6.4 Hz, 1H), 8.30 (d, J=9.2 Hz, 1H).
To a solution of 1-chloro-2-fluoro-5-nitro-4-(trifluoromethyl)benzene (1.80 g, 7.39 mmol) in acetic acid (20 mL) iron (1.24 g, 22.2 mmol) was added and the mixture was stirred 4 h at 80° C. The mixture was filtered, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 40 g, 50 m/min, silica gel, UV 254) to afford the product (1.3 g, 82%). 1H NMR (400 MHz, DMSO-d6) δ 7.41 (d, J=9.6 Hz, 1H), 7.00 (d, J=6.4 Hz, 1H), 5.75 (s, 2H).
To a solution of 5-chloro-4-fluoro-2-(trifluoromethyl)aniline (1.30 g, 6.09 mmol) in acetic acid (5 mL) concentrated HCl (5 mL) was added and the mixture was cooled to −5° C. A solution of NaNO2 (630 mg, 9.13 mmol) in water (2 mL) was added and the mixture was stirred 1 h at 0° C. A solution of tin(II) chloride dihydrate (2.75 g, 12.2 mmol) in concentrated HCl (5 mL) was added slowly at 0° C. The mixture was warmed to rt and stirred 3 h. The mixture was basified to pH=10 by addition of NaOH (1M). The mixture was extracted with EtOAc (2×50 mL). The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (DCM/PE=0/1˜4/1, Silica-CS 40 g, 50 mL/min, silica gel, UV 254) to afford the product (433 mg, 31%). ESI-MS m/z calcd for [C7H5ClF4N2] [M+H]+: 229.0; found: 229.1. 1H NMR (400 MHz, DMSO-d6) δ 7.51 (d, J=6.8 Hz, 1H), 7.48 (d, J=9.2 Hz, 1H), 6.96 (s, 1H), 4.30 (s, 2H).
To a cooled (0° C.) solution of 1,4-bromo-2-fluorobenzene (3.00 g, 11.8 mmol) and NH4NO3 (1.42 g, 17.7 mmol) in DCM (100 mL) trifluoroacetic anhydride (11.5 mL, 82.7 mmol) was added over 15 min. The mixture was stirred 15 min at 0° C. then 2 h at rt. The reaction was quenched with saturated aq NaHCO3 (560 mL) and the phases were separated. The aqueous phase was extracted with DCM and then EtOAc. The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/7, Silica-CS 80 g, 50 m/min, silica gel, UV 254) to afford the product (2.8 g, 35%). 1H NMR (400 MHz, Chloroform-d) δ 8.11 (d, J=6.4 Hz, 1H), 7.46 (d, J=7.2 Hz, 1H).
To a solution of 1,4-dibromo-2-fluoro-5-nitrobenzene (2.80 g, 9.37 mmol) in DMF (25 mL) methyl 2,2-difluoro-2-fluorosulfonylacetate (3.6 g, 18.7 mmol) and CuI (1.78 g, 9.37 mmol) were added and the mixture was stirred 2 h at 80° C. The reaction was quenched with saturated aq NaHCO3 (200 mL) and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine (2×100 mL), dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/7, Silica-CS 80 g, 50 m/min, silica gel, UV 254) to afford the product (1.85 g, 69%). 1H NMR (400 MHz, Chloroform-d) δ 8.16 (d, J=6.0 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H).
To a solution of 1-bromo-2-fluoro-5-nitro-4-(trifluoromethyl)benzene (2.13 g, 7.40 mmol) in acetic acid (20 mL) iron (1.24 g, 22.2 mmol) was added and the mixture was stirred 4 h at 80° C. The mixture was concentrated and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 40 g, 50 m/min, silica gel, UV 254) to afford the product (1.05 g, 55%). 1H NMR (400 MHz, DMSO-d6) δ 7.37 (d, J=9.2 Hz, 1H), 7.15 (d, J=6.0 Hz, 1H), 5.74 (br s, 2H).
To a solution of 5-bromo-4-fluoro-2-(trifluoromethyl)aniline (1.05 g, 4.07 mmol) in acetic acid (5 mL) concentrated HCl (5 mL) was added and the mixture was cooled to −5° C. A solution of NaNO2 (421 mg, 6.10 mmol) in water (2 mL) was added and the mixture was stirred 1 h at 0° C. A solution of tin(II) chloride dihydrate (1.84 g, 8.14 mmol) in concentrated HCl (5 mL) was added slowly at 0° C. The mixture was warmed to rt and stirred 3 h. The mixture was basified to pH=10 by addition of NaOH (1M). The mixture was extracted with EtOAc (2×50 mL). The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (DCM/MeOH=1/0˜4/1, Silica-CS 40 g, 50 m/min, silica gel, UV 254) to afford the product (405 mg, 37%). ESI-MS m/z calcd for [C7H5BrF4N2] [M+H]+: 273.0; found: 273.0. 1H NMR (400 MHz, DMSO-d6) δ 7.66 (d, J=6.0 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H), 6.93 (br s, 1H), 4.30 (br s, 2H).
A solution of 3,7-anhydro-6,8-O-benzylidene-5-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-5-deoxy-4-O-(methoxymethyl)-
To a solution 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-{5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-[3-amino-5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-[3-amino-5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-3-
To a solution of 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-
To a solution of 1-{5-{4,6-O-benzylidene-3-[4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl]-3-deoxy-2-O-methyl-β-
To a solution 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution 1-[3-aminocarbonyl-5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
To a solution of 1-[5-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-β-
A mixture of 2-bromo-5-chloro-3-nitropyridine (9.80 g, 41.3 mmol), methyl 2,2-difluoro-2-fluorosulfonylacetate (11.9 g, 61.9 mmol) and CuI (9.43 g, 49.5 mmol) in DMF (100 mL) was stirred 2 h at 100° C. After cooling to rt, the mixture was poured into water (300 mL) and then extracted with EtOAc (3×100 mL). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 80 g, 40 mL/min, silica gel, UV 254) to give the product (8.8 g, 94%). ESI-MS m/z calcd for [C6H2ClF3N2O2] [M]: 226.0; found: 226.0. 1H NMR (400 MHz, Chloroform-d) δ 8.79 (d, J=2.0 Hz, 1H), 8.16 (d, J=1.6 Hz, 1H).
A solution of 5-chloro-2-(trifluoromethyl)-3-nitropyridine (8.8 g, 38.8 mmol), ammonium hydrochloride (12.5 g, 233 mmol) and iron (10.8 g, 194 mmol) in EtOH (100 mL) and H2O (10 mL) was stirred 6 h at 85° C. The mixture was filtered, concentrated, and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 80 g, 40 mL/min, silica gel, UV 254) to give the product (7.1 g, 93%). ESI-MS m/z calcd for [C6H4ClF3N2] [M+H]+: 197.0; found: 197.2. 1H NMR (400 MHz, Chloroform-d) δ 7.92 (d, J=1.6 Hz, 1H), 7.04 (d, J=2.0 Hz, 1H), 4.25 (br s, 2H).
To a cooled (−5° C.) solution of 3-amino-5-chloro-2-(trifluoromethyl)pyridine (2.50 g, 12.7 mmol) in acetic acid (8.0 mL) concentrated HCl (16.0 mL) was added. A solution of NaNO2 (1.14 g, 16.5 mmol) in water (4.0 mL) was added dropwise over 5 min. The mixture was stirred 45 min at −5° C. Then a cooled (0° C.) solution of tin(II) chloride dihydrate (2.87 g, 12.7 mmol) in concentrated HCl (8.0 mL) was added dropwise over 10 min. The mixture was stirred 2 h at −5° C. Then aqueous NaOH (5 M) was added dropwise at −5° C. to adjust pH to 8. The mixture was extracted with EtOAc (2×100 mL). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over Na2SO4, evaporated, and purified by column chromatography (PE/EtOAc=1/0˜4/1, silica-CS 20 g 20 mL/min, silica gel, UV 254 nm) to afford the product (1.8 g, 67%). ESI-MS m/z calcd for [C6H5ClF3N3] [M+H]+: 212.0; found: 212.2. 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J=2.0 Hz, 1H), 7.81 (d, J=2.0 Hz, 1H), 5.94 (s, 1H), 3.65 (s, 2H).
A solution of 2,5-dibromo-3-nitropyridine (2.00 g, 7.09 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (2.05 g, 10.6 mmol) and CuI (1.62 g, 8.51 mmol) in DMF (20.0 mL) was stirred 2 h at 100° C. After cooling to rt, the mixture was poured into water (50 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over Na2SO4, evaporated and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 20 g, 20 mL/min, silica gel, UV 254) to give the product (1.8 g, 94%). ESI-MS m/z calcd for [C6H2BrF3N2O2] [M]: 269.9; found: 270.0. 1H NMR (400 MHz, Chloroform-d) δ 8.90 (d, J=1.6 Hz, 1H), 8.30 (d, J=1.6 Hz, 1H).
To a solution of 5-bromo-3-nitro-2-(trifluoromethyl)pyridine (1.8 g, 6.64 mmol) in EtOH/H2O (22 mL, 10:1) iron (1.86 g, 33.2 mmol) and NH4Cl (2.13 g, 39.9 mmol) were added and the mixture was stirred 6 h at 85° C. The mixture was concentrated and purified by column chromatography (PE/EtOAc=1/0˜4/1, Silica-CS 20 g, 20 mL/min, silica gel, UV 254) to give the product (1.45 g, 91%). ESI-MS m/z calcd for [C6H4BrF3N2] [M+H]+: 241.0; found: 240.9. 1H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J=1.6 Hz, 1H), 7.21 (d, J=1.6 Hz, 1H), 4.22 (br s, 2H).
To a cooled (−5° C.) solution of 5-bromo-2-(trifluoromethyl)pyridin-3-amine (600 mg, 2.49 mmol) in acetic acid (3.0 mL) concentrated HCl (9.0 mL) was added followed by dropwise addition of a solution of NaNO2 (223 mg, 3.24 mmol) in water (1 mL). The resulting mixture was stirred 45 min at −5° C. Tin(II) chloride dihydrate (1.69 g, 7.47 mmol) dissolved in concentrated HCl (3.0 mL) was added dropwise at 0° C. The resulting mixture was stirred 2 h at −5° C. Water (30 mL) was added and the pH was adjusted to 8 by dropwise addition of aq NaOH (5 M). The aqueous phase was extracted with EtOAc (2×50 mL). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over Na2SO4, evaporated, and purified by column chromatography (EtOAc/PE=0/1˜1/4, Silica-CS 20 g, 20 m/min, silica gel, UV 254) to afford the product (350 mg, 55%). ESI-MS m/z calcd for [C6H5BrF3N3] [M+H]+: 256.0; found: 256.1. 1H NMR (400 MHz, Chloroform-d) δ 7.98 (s, 2H), 5.93 (s, 1H), 3.64 (br s, 2H).
A solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-D-glycero-L-manno-2-octulose (85 mg, 0.26 mmol) in N,N-dimethylformamide dimethyl acetal (3 mL) was stirred 3 h at 80° C. The mixture was concentrated to dryness and the residue was dissolved in EtOH (5.0 mL). [4,5-Dichloro-2-(trifluoromethyl)phenyl]hydrazine (75 mg, 0.31 mmol) and concentrated HCl (0.2 mL) were added and the mixture was stirred 2 h at 80° C. The mixture was cooled to rt, poured into aq NaHCO3 (20 mL) and extracted with EtOAc (2×30 mL). The combined organic phases were washed with brine, dried with Na2SO4, and concentrated. The residue was purified by column chromatography (PE/EtOAc=1/0˜2/1, Silica-CS 4 g, 12 mL/min, silica gel, UV 254) to afford the product (20 mg, 16%). ESI-MS m/z calcd for [C17H16Cl2F3N5O4] [M+H]+: 482.1; found: 482.2.
A solution of 3,7-anhydro-5-azido-6,8-O-benzylidene-5-deoxy-4-O-methyl-
To a solution of 1-[3-aminocarbonyl-3-(3-azido-4,6-O-benzylidene-3-deoxy-2-O-methyl-3-
| Number | Date | Country | Kind |
|---|---|---|---|
| 20216480.2 | Dec 2020 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/086975 | 12/21/2021 | WO |
